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1. Introduction 
This report describes and summarises results 
from the fifteenth proficiency test trial conducted 
by the National Food Institute (DTU Food) as 
the EU Reference Laboratory for Antimicrobial 
Resistance (EURL-AR). This proficiency test 
focuses on antimicrobial susceptibility testing 
(AST) of Salmonella and Campylobacter and is 
the eigth External Quality Assurance System 
(EQAS) conducted for these microorganisms 
(the first was EQAS 2006). In addition, the 
proficiency test for the fifth time includes an 
optional element consisting of genotypic 
characterization by PCR/sequencing of 
antimicrobial resistance genes. This optional 
component included characterization of genes 
related to production of extended spectrum 
cephalosporinases (ESC) in the ESC-producing 
Salmonella test strains. 
This EQAS aims to: i) monitor the quality of 
AST results produced by National Reference 
Laboratories (NRL-AR), ii) identify laboratories 
which may need assistance to improve their 
performance in AST, and iii) determine possible 
topics for further research or elaboration. 
In reading this report, the following important 
considerations should be taken into account: 
1) Expected results were generated by 
performing Minimum Inhibitory Concentration 
(MIC) determinations for all test strains in two 
different occasions at the Technical University 
of Denmark, National Food Institute (DTU-
FOOD). These results were then verified by the 
United States Food and Drug Administration 
(FDA), Centre for Veterinary Medicine. Finally, a 
fourth MIC determination was performed at 
DTU-FOOD after preparation of the agar stab 
culture for shipment to participants to confirm 
that the vials contained the correct strains with 
the expected MIC values. 
2) Evaluation is based on interpretations of 
AST values determined by the participants. This 
is in agreement with the method used by MS to 
report AST data to the European Food Safety 
Authority (EFSA), and complies with the main 
objective of this EQAS, i.e. “to assess and 
improve the comparability of surveillance and 
antimicrobial susceptibility data reported to 
EFSA by the different NRLs”, as stated in the 
protocol. 
3) The EURL-AR network agreed on setting the 
accepted deviation level for laboratory 
performance on AST to 5%. For the optional 
genotypic characterisation, no specific 
acceptance level has been set. 
Evaluation of a result as “deviating from the 
expected interpretation” should be carefully 
analyzed in a self-evaluation procedure 
performed by the participant and considering 
the introduction of corrective actions in the 
laboratory, if necessary. Note, that since 
methods used for MIC determination have 
limitations, it is not considered a mistake to 
obtain a one-fold dilution difference in the MIC 
of a specific antimicrobial when testing the 
same strains. If, however, the expected MIC is 
close to the breakpoint value for categorizing 
the strain as susceptible or resistant, a one-fold 
dilution difference - which is acceptable - may 
result in two different interpretations, i.e. the 
same strain can be categorized as susceptible 
and resistant. This result will be evaluated as 
correct in one case and incorrect in the other if 
the evaluation is based on interpretation of MIC 
values. This report evaluates AST- 
interpretations, therefore some participants may 
find their results classified as incorrect even 
though the actual MIC they reported is only a 
one-fold dilution different from the expected 
MIC. In these cases, the participants should be 
confident about the good quality of their 
performance of AST by MIC. In the organization 
of the EQAS, we try to avoid these situations by 
choosing test strains with MIC values distant 
from the breakpoints for resistance, which is not 
always feasible for all strains and all 
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antimicrobials. Therefore, the EURL-AR 
network unanimously established in 2008 that if 
there are less than 75% correct results for a 
specific strain/antimicrobial combination, the 
reasons for this situation must be further 
examined and, on selected occasions explained 
in details case by case, these results may 
subsequently be subtracted from the evaluation 
report.  
This report is approved in its final version by a 
technical advisory group composed by 
competent representatives from all NRL-ARs. 
This group meets annually at the EURL-AR 
workshop. 
 
All conclusions presented in this report are 
publically available. Participating laboratories 
are identified by codes and each code is known 
only by the corresponding laboratory. The full 
list of laboratory codes is confidential 
information known only by relevant 
representatives of the EURL-AR and the EU 
Commission.  
The EURL-AR is accredited by DANAK as 
provider of proficiency testing (accreditation no. 
516); working with zoonotic pathogens and 
indicator organisms as bacterial isolates 
(identification, serotyping and antimicrobial 
susceptibility testing). 
2. Materials and Methods  
2.1 Participants in EQAS 2013 
A pre-notification (App. 1) to announce the 
EURL-AR EQAS on AST of Salmonella and 
Campylobacter was distributed on the 25th June 
2013 by e-mail to the 41 NRLs in the EURL-AR-
network including all EU countries (except 
Luxembourg where no NRL-AR was 
designated) and including Iceland, Norway, 
Serbia, Switzerland and Turkey. One laboratory 
did not participate as they had neither 
Salmonella nor Campylobacter AST as their 
field of responsibility. Serbia, Turkey and one 
NRL did not participate in this year’s iteration. In 
addition to the AST of Salmonella and 
Campylobacter, an optional genotypic 
characterization by PCR/sequencing of 
antimicrobial resistance genes of the ESC-
producing Salmonella test strains was offered.  
Appendix 2 shows that 33 of the 37 
participating NRLs were appointed by the 
individual Member States’ Competent Authority. 
Two NRLs were enrolled in the network on 
equal terms as the designated NRLs, based on 
their participation in an EU funded concerned 
action (FAIR5-QLK2-2002-01146), the ARBAO 
II project (Antibiotic Resistance in Bacteria of 
Animal Origin). These two laboratories, together 
with those in Norway and Switzerland, were 
charged a fee for their participation in the 
EQAS, whereas the NRLs from EU Member 
States participated free of charge. 
Figure 1 illustrates that of the 30 participating 
countries, 28 tested both Salmonella and 
Campylobacter. Two countries, for different 
reasons, uploaded Salmonella results, only, for 
evaluation (Greece and Malta), and one country 
uploaded results both for Salmonella and 
Campylobacter, however, for Campylobacter 
they delivered species identification, only. Eight 
laboratories  participated in the optional 
genotypic characterisation of the ESC-
producing Salmonella test strains (not 
illustrated in Figure 1; see Appendix 2). 
The results from the NRLs designated by the 
MS are presented and evaluated in this report 
in addition to national reference laboratories in 
affiliated non-MS; i.e. results from 30 countries 
consisting of 34 laboratories submitting 
Salmonella results and 30 laboratories 
submitting Campylobacter results. Results from 
the two laboratories not designated by the MS 
but enrolled on equal terms as these are not 
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further presented or evaluated in this report. 
  
 
 
Figure 1: Participating countries that performed antimicrobial susceptibility testing of Salmonella or both 
Salmonella and Campylobacter.  
2.2 Strains  
Eight Salmonella strains and eight 
Campylobacter strains were selected for this 
trial among isolates from the strain collection at 
DTU Food on the basis of antimicrobial 
resistance profiles and MIC values. For quality 
assurance purposes, one strain per bacterial 
species has been included in all EQAS 
iterations performed to date, representing an 
internal control. 
Prior to distribution of the strains, AST was 
performed on the Salmonella and 
Campylobacter strains at DTU Food and 
verified by the US Food and Drug 
Administration (FDA). When MIC-values were 
not in agreement but varied +/- one MIC-step, 
the value obtained by DTU Food was selected 
as the reference value. The obtained MIC 
values served as reference for the test strains 
(App. 3a and 3b). Results from the following 
antimicrobials were not verified by FDA: 
cefepime, cefotaxime, cefotaxime/clavulanic 
acid, ceftazidime, ceftazidime/clavulanic acid, 
colistin, ertapenem, imipenem, meropenem, 
and trimethoprim for Salmonella and 
furthermore, chloramphenicol and streptomycin 
for Campylobacter. 
Reference strains Escherichia coli CCM 3954 
(ATCC 25922) and Campylobacter jejuni CCM 
6214 (ATCC 33560) were provided to new 
participating laboratories with instructions to 
store and maintain them for quality assurance 
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purposes and future EQAS trials. 
 
2.3 Antimicrobials  
The antimicrobials tested in this EQAS are 
listed in the protocol (App. 4b).  
The antimicrobials tested were changed in 
relation to previous trials and were - to the 
extent possible - adjusted towards the panel of 
antimicrobials listed in the new the EU 
regulation (Decision 2013/652/EU). 
Antimicrobials listed in the new regulation for 
which MIC-panels for AST and interpretative 
criteria for interpretation of the result were 
available, were included for the proficiency test. 
Guidelines for performing AST were set 
according to the Clinical and Laboratory 
Standards Institute (CLSI) document; M7-A9 
(2012) “Methods for Dilution Antimicrobial 
Susceptibility Tests for Bacteria That Grow 
Aerobically; Approved Standard - Ninth Edition”; 
M100-S23 (2013) “Performance Standards for 
Antimicrobial Susceptibility Testing” (Twenty-
Third Informational Supplement) and document 
VET01-A4 (2013) “Performance Standards for 
Antimicrobial Disk and Dilution Susceptibility 
Tests for Bacterial Isolated From Animals” 
(Approved Standard – Fourth Edition). 
MIC results were interpreted by using EUCAST 
epidemiological cut-off values (www.eucast.org) 
as described and listed in the protocol (App. 4). 
Where EUCAST interpretative criteria were not 
available, CLSI-interpretative criteria were listed 
as the alternative. Results of ESC detection 
tests were interpreted according to the most 
recent EFSA recommendations (EFSA Journal 
2012; 10(6):2742). 
The selection of antimicrobials used in the trial 
for Salmonella were: ampicillin (AMP), cefepime 
(FEP), cefotaxime (CTX), cefotaxime/clavulanic 
acid (CTX/Cl), cefoxitin (FOX), ceftazidime 
(CAZ), ceftazidime/clavulanic acid (CAZ/Cl), 
chloramphenicol (CHL), ciprofloxacin (CIP), 
colistin (COL), ertapenem (ERT), gentamicin 
(GEN), imipenem (IMI), meropenem (MER), 
nalidixic acid (NAL), sulfonamides 
(sulfamethoxazole) (SMX), tetracycline (TET) 
and trimethoprim (TMP). 
Minimum Inhibitory Concentration (MIC) 
determination of the Salmonella test strains was 
performed using the Sensititre system from 
Trek Diagnostic Systems Ltd, UK. For ESC 
confirmatory test, the analysis included MIC 
determination by microbroth dilution (panel 
code ESB1F), and in addition, for the 
antimicrobials cefotaxime/clavulanic acid, 
cefoxitin, ceftazidime/clavulanic acid, tests were 
performed using E-test from AB-Biodisk, 
Sweden.  
For Campylobacter the following antimicrobials 
were included: chloramphenicol (CHL), 
ciprofloxacin (CIP), erythromycin (ERY), 
gentamicin (GEN), nalidixic acid (NAL), 
streptomycin (STR), and tetracycline (TET). 
MIC determination was performed using the 
Sensititre systems from Trek Diagnostic 
Systems Ltd, UK, according to guidelines from 
the CLSI document M45-A2 (2010) “Methods 
for Antimicrobial Dilution and Disk Susceptibility 
Testing of Infrequently Isolated or Fastidious 
Bacteria” (Approved Guideline – Second 
Edition) and VET01-S2 (2013) “Performance 
Standards for Antimicrobial Disk and Dilution 
Susceptibility Tests for Bacterial Isolated From 
Animals” (Second Informational Supplement). 
This year, participants of the Campylobacter 
EQAS were additionally requested to identify 
the species of the Campylobacter spp. as either 
C. jejuni or C. coli. 
2.4 Distribution 
On 14th October 2013, bacterial strains in agar 
stab cultures (Salmonella spp.) or charcoal 
swabs in transport media (Stuarts) 
(Campylobacter spp.) together with a welcome 
letter (App. 4a) were dispatched in double pack 
containers (class UN 6.2) to the participating 
laboratories according to the International Air 
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Transport Association (IATA) regulations as 
UN3373, biological substances category B.  
2.5 Procedure 
Protocols and all relevant information were 
uploaded on the EURL-AR website 
(http://www.eurl-ar.eu), thereby EQAS 
participants could access necessary information 
at any time.  
Participants were instructed to subculture 
charcoal swabs immediately, store the agar 
stabs 4ºC (dark) and the freeze-dried strains 
cool and dark until performance of AST. 
Information related to the handling of the test 
strains and reference strains (App. 4b, c, d, e). 
Participants receiving an ATCC reference strain 
were requested to save and maintain this strain 
for future proficiency tests. 
The participants were instructed to apply the 
interpretative criteria listed in the protocol (App. 
4). Instructions for interpretation of AST results 
allowed for categorization of results as resistant 
or susceptible. Categorisations as ‘intermediate’ 
were not accepted.  
The EURL-AR is aware that there are two 
different types of interpretative criteria of 
results, clinical breakpoints and epidemiological 
cut-off values. The terms ‘susceptible’, 
‘intermediate’ and ‘resistant’ should be reserved 
for classifications made in relation to the 
therapeutic application of antimicrobial agents. 
When reporting data using epidemiological cut-
off values, bacteria should be reported as ‘wild-
type’ or ‘non-wild-type’ (Schwarz et al., 2010). 
Due to the different methods of AST used by 
the participants and also to simplify the 
interpretation of results, throughout this report, 
we will still maintain the terms susceptible and 
resistant, even in cases where we are referring 
to wild-type and non-wild-type strains. 
The aim is that only MIC methods are used 
when performing AST for monitoring conducted 
by the Commission, and thereby also when 
performing the EURL-AR EQAS’s. 
Consequently, it was decided in May 2007 by 
the participants at the EURL-AR workshop that 
the NRLs should work towards harmonising to 
MIC methods for these AST analyses. 
Additionally, it was agreed that all NRLs should 
work towards covering the antimicrobial panel 
and epidemiological cut-off values 
recommended by the EURL-AR. For this 
EQAS, the participants were instructed to use 
as many as possible of the antimicrobials listed, 
using the method carried out when performing 
monitoring for EFSA. 
It should be noted that for AST of 
Campylobacter the EURL-AR does not 
recommend the use of either disk diffusion or E-
test for AST of Campylobacter. I.e. only results 
obtained by broth or agar dilution methods are 
accepted for this EQAS, as also agreed at the 
EURL-AR workshop 2009.  
A mandatory part of the proficiency test was to 
detect ESC-producing strains and interpret 
results according to recommendations by 
EUCAST as described in the protocol.  
Results from QC reference strains would 
consist of MIC values for the reference strains 
E. coli (ATCC 25922) and C. jejuni (ATCC 
33560) or, for E. coli (ATCC 25922), the 
inhibition zone diameters in millimetres. The 
results were evaluated towards the quality 
control ranges according to the relevant 
guidelines; i.e. the CLSI documents VET01-S2 
(2013) or M100-S23 (2013) (App. 5). 
For the optional genotypic characterisation of 
the ESC-producing Salmonella test strains, 
participating laboratories were requested to 
report the genes conferring resistance to 
extended-spectrum beta lactam antimicrobials. 
The organizers, however, decided to include 
none-ESC TEM-genes and OXA-genes 
resulting in blaTEM-1 and blaOXA-30 registered as 
expected genes, also. The genes listed in the 
table in the protocol (App. 4b) were included in 
the test. Identification of additional genes not 
listed in the protocol was not evaluated by the 
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database. The results were evaluated based on 
the actual genes and variants identified. 
The participating laboratories were encouraged 
to use their own laboratory’s method(s) for the 
genotypic characterisation. The expected 
results for this component of the EQAS were 
obtained by whole-genome-sequencing and 
subsequent analysis using the ResFinder 1.4 
platform available at 
http://cge.cbs.dtu.dk/services/ResFinder/. The 
positive identification of genes was not verified 
elsewhere. 
All participating laboratories were invited to 
enter the obtained results into an electronic 
record sheet at the EURL-AR web-based 
database through a secured individual login and 
password. The record sheet contained space 
for reporting the results obtained for the QC 
reference strains. Alternatively, it was offered 
the possibility to fill-in a record sheet (provided 
with the protocol) and to send it to the EURL-
AR by fax, mail or email. 
In addition, participants were encouraged to 
complete an evaluation form available at the 
EURL-AR database with the aim to improve 
future EQAS trials. 
The database was finally closed and 
evaluations were made available to participants 
on the 11th December 2013. After this date, the 
participants were invited to login to retrieve an 
individual, database-generated report which 
contained an evaluation of the submitted results 
including possible deviations from the expected 
interpretations. Deviations in the interpretation 
as resistant or susceptible were categorised as 
‘incorrect’, as were also deviations concerning 
confirmation of an isolate as extended spectrum 
beta-lactamase- (ESBL-), ampC- or 
carbapenemase-producer. 
Upon review of the submitted data, the EQAS 
organizers came to realise that it was 
necessary to make changes in the EQAS-
database as regards the expected results of 
two strains, i.e. S-8.4 and S-8.5. Detailed 
information was  sent to the participants on 
February 5th 2014 with description of 
background for the changes and 
encouragement to login to the database again 
to retrieve updated evaluation reports. 
3. Results 
The participants were asked to report results, 
including MIC values or inhibition zone 
diameters obtained by DD together with the 
categorisation as resistant or susceptible. Only 
the categorisation was evaluated, whereas the 
MIC values and disk diffusion inhibition zones 
were used as supplementary information. 
3.1 Data omitted from the report 
As mentioned in the introduction, the EURL-AR 
network established that data should be 
examined and possibly omitted from the 
general analysis if there are less than 75% 
correct results based on strain/antimicrobial 
combination (see Appendix 8 for an overview of 
correct/incorrect results). In the present EQAS 
this occurred in one case: for the combination 
of the test strain S-8.4/meropenem with a level 
of disagreement with the expected results at 
62% based on 13 results of which 5 were 
assigned with the expected interpretation as 
resistant. The testing and interpretation in 
relation to this strain/antimicrobial combination 
was complex and ultimately, it was decided to 
leave out the database evaluation as 
correct/incorrect of both the categorization in 
relation to meropenem resistant and the 
classification as ESBL/AmpC/carbapenemase-
producer, and consequently leave this data out 
from further evaluation in this report  
This conclusion was based on the following; 1) 
EUCAST cut off for meropenem is R>0.125; 2) 
in the currently available MIC-panels, the 
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EUCAST cutoff for meropenem is not covered 
(lowest meropenem dilution is 1 mg/L); 3) 
interpretative criteria for disk diffusion results 
corresponding to the EUCAST cut off value are 
not available; 4) to obtain an MIC-value that 
could be interpreted according to the 
interpretative criteria listed in the protocol, the 
EQAS participants had to perform AST by E-
test or agar dilution; 5) at the EURL-AR, the 
expected value was obtained by performing 
AST by E-test; 6) participants submitted results 
based on either microbroth dilution, DD and E-
test (for each method results reported by one 
third of NRLs); and 7) some participants 
submitted an MIC-value but no interpretation or 
an interpretation but no MIC-value. 
Follow-up at the EURL-AR on the strain S-8.4 
regarding the MIC for meropenem included 
additional E-tests on a number agar sticks that 
had been stored since the production for the 
EQAS. These results indicated that the 
expected value should be adjusted and lowered 
to 0.125. Based on these results together with 
the results submitted by the participants, it was 
decided to adjust the expected value for 
meropenem to an MIC of 0.125 with an 
interpretation as ‘susceptible’.  
Classifying the phenotypic results according to 
the EFSA recommendations (EFSA Journal 
2012; 10(6):2742), the updated conclusion is  
‘presumptive pAmpC phenotype’. This 
classification is not correct, and the EURL-AR 
has decided not to follow the EFSA 
recommendations in this particular case, since 
the strain expresses phenotypical resistance to 
e.g. ertapenem and imipenem and harbours the 
VIM-2-gene.  
3.2 Methods  
In the data analysis, results were grouped 
according to the methods used by the 
participants. The agar dilution method and MIC 
determination were evaluated together as they 
are both quantitative methods giving results 
corresponding to the MIC of the bacterial strain 
tested.  
In the Salmonella trial, 30 laboratories used 
MIC determination (28 used microbroth and two 
agar dilution), and four laboratories used disk 
diffusion. For the Campylobacter trial, all 30 
included laboratories reported the use of MIC 
determination (microbroth or agar dilution).  
3.3 Deviations, overall 
The list of deviations is shown in Appendix 8a 
and 8b. Figure 2 shows the total percentage of 
deviations from the expected results of AST 
performed by participating laboratories. The 
internal control strain mainly followed the trend 
in deviation level of the different EQAS trials 
(Figure 2). The deviation level in 2013 is 
acceptable for both the Salmonella and the 
Campylobacter trials. For the Campylobacter 
AST, however, it appears that there has been 
an increase in the level of deviations, to 3.5% in 
2013 compared to 2.1% in 2012. Four 
laboratories’ high deviation levels (between 
12.5% and 19.0%) caused this increase. 
3.3.1 Salmonella trial  
For the Salmonella strains, 99.3% of the AST’s 
were interpreted correctly. Figure 3 shows the 
total percentage of deviations from the 
expected results of AST performed by MIC-
methods as opposed to disk diffusion. The 
deviation percentage is significantly higher 
(p<0.05) when AST is performed by disk 
diffusion compared to a MIC-method.  
The number of AST’s performed and the 
percentage of correct results for the individual 
strains in the EQAS, are listed in Table 1. 
Variations of obtained correct results ranged 
from 97.9-99.5% for Salmonella. Table 2 
illustrates the percentage of correct AST per 
antimicrobial by bacterial species. The level of 
correct AST was above 97.7% for the 
Salmonella test strains. Sulfonamides exhibited 
the lowest deviation level.  
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Figure 2: A comparison between the EURL-AR EQAS’s since 2006, showing the total percentage of deviations 
for antimicrobial susceptibility testing performed by participating laboratories.  
 
Figure 3: The total percentage of deviations for AST’s 
performed using MIC-methods as opposed to disk 
diffusion. 
ESC-producing Salmonella test strains 
Confirmation of beta-lactamase production is a 
mandatory component of this EQAS.  
According to the protocol, which was based on 
the EFSA recommendations, the confirmatory 
test for ESC-production requires use of both 
cefotaxime (CTX) and ceftazidime (CAZ) alone 
and in combination with a β-lactamase inhibitor 
for either antimicrobial agent tested in 
combination with clavulanic acid vs. its MIC 
when tested alone (three dilution steps 
difference; MIC CTX:CTX/Cl or CAZ:CAZ/Cl 
ratio ≥8) or ii) a ≥5 mm increase in a zone 
diameter for either antimicrobial agent tested in 
combination with clavulanic acid vs. its zone 
when tested alone (CLSI M100 Table 2A; 
Enterobacteriaceae). The presence of synergy 
indicates ESBL-production. Resistance to 
cefepime gives further indication of ESBL 
production.  
Confirmatory test for carbapenemase 
production requires the testing of meropenem 
(MER).  
Detection of AmpC-type beta-lactamase 
producing bacteria can be performed by testing 
the isolates for susceptibility to cefoxitin (FOX). 
Resistance to FOX could indicate the presence 
of an AmpC-type beta-lactamase, which may be 
verified by PCR and sequencing. 
The classification of the phenotypic results 
should be based on the most recent EFSA 
recommendations (EFSA 2012), indicating: 
• Presumptive ESBL-phenotype: strains 
with positive synergy test, susceptible to 
cefoxitin and resistant to cefepime 
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• Presumptive ESBL+pAmpC-phenotype: 
strains with positive or negative synergy 
test, resistant to cefoxitin and resistant to 
cefepime 
• Presumptive pAmpC phenotype: strains 
with negative synergy test  
• Presumptive carbapenemase phenotype: 
strain resistant to meropenem 
• Unusual phenotype: any other 
combinations 
In this EQAS, all laboratories uploaded results 
for the strains harbouring resistance to the 
cephalosporins tested. 
The strain S-8.4 was a carbapenemase 
producer, however, results for this will not be 
further evaluated in this report (see description 
above (section 3.1)), S-8.5, S-8.6 and S-8.7 
were ESC producers. For the strain S-8.5, both 
interpretations as unusual phenotype and ESBL 
phenotype were considered correct. The 
categorization as ‘unusual’ was based on the 
phenotypic testing, whereas the categorization 
as ESBL-producer required additional genotypic 
testing. Phenotypic and genotypic tests 
indicated that this particular strain expresses 
synergy when testing CTX and CTX/Cl as well 
as CAZ and CAZ/Cl, it is susceptible to 
cefoxitin. In addition, the strain does not 
express resistance to cefepime (in the absence 
of EUCAST epidemiological cut-off values, 
CLSI interpretative criteria were applied) but 
harbours a CTX-M9-gene. 
Deviations from expected results in relation to 
the strains S-8.5, S-8.6 and S-8.7 were as 
follows: 
In total the categorization as ESBL-, pAmpC- or 
carbapenemase-producer was incorrect in 12 
cases, with five of the incorrect results 
submitted for strains which were not resistant to 
cephalosporins or carbapenems. Six of the 12 
incorrect results related to one laboratory (#58), 
whereas the other six related to six different 
laboratories. Of these, four had detected 
cefepime resistance for strain S-8.7 (#6, #18, 
#30 and #56) and therefore categorized this as 
unusual phenotype, one (#22) had registered  
S-8.3 as unusual phenotype, the registered 
data for this strain, however, did not indicate 
this. Finally, laboratory #41 had observed 
imipenem resistance for strain S-8.6 and based 
on this categorized the strain to have an 
unusual phenotype. For laboratory #58 the high 
number of incorrect results in this context 
appears to be related to the handling of the 
strains or other procedures in the laboratory.   
3.3.2 Campylobacter trial 
For the Campylobacter strains, 96.5% of AST’s 
were correctly tested. Table 1 presents that the 
variation in the obtained correct results ranged 
from 93.9-98.9% and Table 2 illustrates that the 
percentage of correct AST per antimicrobial 
was above 93.2% for the Campylobacter test 
strains with nalidixic acid exhibiting the lowest 
level. 
For the first time, the participants were 
requested to identify the Campylobacter 
species. The exercise went very well with 30 
laboratories delivering in total 240 results with 
only three identifications incorrect. One 
participant did not upload data for 
Campylobacter identity (Lab #23). The 
registered deviations were obtained by two 
participants who failed to identify one strain 
(#40) and two strains (#36), respectively. 
3.4 Deviations by laboratory 
Figure 4 and 5 illustrate the percentage of 
deviations for each participating laboratory. The 
laboratories are ranked according to their 
performance determined by the percentage of 
deviating results in the antimicrobial 
susceptibility tests. 
3.4.1 Salmonella trial  
Thirty-two of the laboratories obtained a result 
within the acceptance limit at 5% deviations for 
the Salmonella strains. The maximum  
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Table 1. The number of AST performed and the percentage of correct results for each strain of Salmonella and 
Campylobacter. 
EQAS 2013 – Salmonella  EQAS 2013 – Campylobacter 
Test strain AST in total % correct  Test strain AST in total % correct 
S-8.1 382 99.0  C-8.1 (C. coli) 179 93.9 
S-8.2 381 99.5  C-8.2 (C. coli) 180 97.8 
S-8.3 383 99.5  C-8.3 (C. jejuni) 174 94.8 
S-8.4 369 99.7  C-8.4 (C. jejuni) 161 96.9 
S-8.5 382 98.2  C-8.5 (C. jejuni) 180 97.8 
S-8.6 383 99.7  C-8.6 (C. coli) 180 96.1 
S-8.7 384 99.5  C-8.7 (C. coli) 180 96.1 
S-8.8 382 97.9  C-8.8 (C. coli) 180 98.9 
 
Table 2: Percentage of correct antimicrobial 
susceptibility tests per antimicrobial by 
microorganism.  
Antimicrobial Salmonella Campylobacter 
Ampicillin 99.6 - 
Cefotaxime 99.6 - 
Ceftazidime 98.9 - 
Chloramphenicol 99.3 - 
Ciprofloxacin 98.2 96.6 
Colistin 98.3 - 
Erythromycin - 97.5 
Gentamicin 99.6 99.6 
Meropenem 100 - 
Nalidixic acid 99.3 93.2 
Streptomycin - 96.6 
Sulphonamides 97.7 - 
Tetracycline 99.6 95.7 
Trimethoprim 99.6 - 
 
percentage of deviations was 7.4%. The 
performance of two (6%) laboratories resulted 
in a deviation level above the level of 
performance expected by the EURL-AR (#42 
and #58), however, none of the laboratories are 
regarded as outliers. 
3.4.2 Campylobacter trial 
In the Campylobacter trial, most laboratories 
performed very well. Applying the 5% 
acceptance threshold, 24 of 30 participating 
laboratories performed acceptably, with 13 
laboratories having no deviations (Figure 5). Six 
laboratories present a deviation level above the 
5% acceptance level (#6, #12, #22, #29, #37 
and #44) and of these, the four with deviation 
levels at 12.5%, 12.5%, 14.6% and 19.0% were 
regarded as outliers (#29, #37, #6, and #22). 
3.5 Deviations by reference strains  
In the following section, deviations are defined 
as results of antimicrobial susceptibility tests on 
the reference strain that are outside the quality 
control (QC) acceptance intervals (App. 5).  
Values from the participants’ testing of the QC 
strains are listed in Appendix 6a and 6b, and in 
Table 4-5. For both the Salmonella and 
Campylobacter trial, all laboratories uploaded 
data from QC-testing on the relevant reference 
strain. 
Appendix 6a indicates that of laboratories 
performing disk diffusion to test the E. coli 
reference strain (ATCC 25922), all but three of 
the obtained results were within the QC-range. 
Results from #15 for colistin and for #45 for 
ampicillin and gentamicin were slightly below or 
above the QC-range. 
From the 26 laboratories submitting AST-results 
for the reference strain E. coli ATCC 25922 
tested by MIC determination, eight laboratories 
produced in all 9 values outside the QC-limit. 
Table 4 illustrates the obtained results which 
are shown in full in Appendix 6a.  
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Table 3: Overview of ESBL-, pAmpC- and carbapenemase-producing Salmonella test strains and proportion of 
laboratories that obtained the expected result; number and percentages of laboratories which correctly detected and 
confirmed the ESBL-, pAmpC- and carbapenemase-producing Salmonella strains. Fields shaded in grey with numbers in 
italics indicate an unexpected result. 
 Strain S-8.4 Strain S-8.5 Strain S-8.6 Strain S-8.7 
ESC-genes harboured in the test strain 
blaVIM-2 
blaTEM-1 
blaCTX-M-9 
blaTEM-1 
blaCTX-M-3 
blaOXA-30 
blaTEM-52 
ESBL-, pAmpC- and carbapenemase-producing 
strain – expected results 
Carbapenemase ESBL unusual  ESBL ESBL 
Obtained 
results 
Confirmed ESBL-producer NA 22/34 (65%) 33/34 (97%) 29/34 (85%) 
Confirmed pAmpC-producer NA - - - 
Confirmed carbapenemase-producer NA - - - 
Confirmed unusual phenotype NA 11/34 (32%) 1/34 (3%) 4/34 (12%) 
Not ESBL-, pAmpC-  
or carbapenemase-producing 
NA 1/34 (3%) - 1/34 (3%) 
NA: Not applicable; see explanation above in section 3.1 
 
 
Figure 4: Individual participants’ deviations in percent of their total number of Salmonella AST’s. An asterisk indicates 
that the laboratory performed AST using disk diffusion 
 
Figure 5: Individual participants’ deviations in percent of their total number of Campylobacter AST’s. 
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Table 5 presents the proportion of laboratories 
with results for the C. jejuni reference strain 
ATCC 33560 below or above the QC interval. 
Nine deviations were seen, three presented by 
one laboratory (#21) and the remaining by six 
laboratory with one each. 
3.6 Genotypic characterisation 
For the optional genotypic characterisation of 
the ESC-producing Salmonella test strains, 
eight laboratories participated. In Appendix 9, 
information is collected on detected genes, 
genes which were tested but not detected, 
primers used, and references for the method 
used. One laboratory performed whole genome 
sequencing of the ESC-producing Salmonella, 
the remaining seven laboratories indicated the 
use of various types of conventional PCR to 
identify the relevant genes. 
Table 6 indicate the obtained results, both on 
gene and variant level. Moreover, Figure 6 
indicates that the discordant results were 
submitted by three laboratories. Additional 
genes/variants not correlating with the expected 
were also found indicating false positive results. 
The laboratories which obtained these results 
should evaluate the procedure to assess how 
the relevant test could be improved in the 
future. 
 
Figure 6: Individual participants’ deviations in percent 
of their total number of results from the genotypic 
characterization.  
*Note, laboratory numbers are different from those 
assigned in the susceptibility testing component. 
Table 4 Obtained values for AST of E. coli ATCC 25922 
by MIC determination. AMP; ampicillin, FEB; cefepime 
CTX; cefotaxime, FOX; cefoxitin, CAZ; ceftazidime, 
CHL; chloramphenicol, CIP; ciprofloxacin, COL; colistin, 
ERT: ertapenem, GEN; gentamicin, IMI; imipenem, 
MER; meropenem, NAL; nalidixic acid, SMX; 
sulphonamides, TET; tetracycline, TMP; trimethoprim. 
MIC determination E. coli ATCC 25922 
Anti-
microbial 
Proportion 
outside QC 
range 
Obtained values in MIC 
steps (min/max) 
Below 
lower QC 
limit 
Above 
upper QC 
limit 
AMP 0/31 (0%) - - 
FEB 0/5 (0%) - - 
CTX 0/31 (0%) - - 
FOX 0/7 (0%) - - 
CAZ 0/30 (0%) - - 
CHL 0/31 (0%) - - 
CIP 3/31 (10%) - 1 step 
COL 0/27 (0%) - - 
ERT 2/4 (50%) - 5 steps 
GEN 0/31 (0%) - - 
IMI 1/5 (20%) - 1 step 
MER 0/7 (0%) - - 
NAL 1/31 (3%) 1 step - 
SMX 2/21 (10%) - 2 steps 
TET 0/31 (0%) - - 
TMP 0/31 (0%) - - 
Table 5 Obtained values for AST of C. jejuni ATCC 
33560 by MIC determination. CIP; ciprofloxacin, ERY; 
erythromycin, GEN; gentamicin, NAL; nalidixic acid, 
TET; tetracycline. 
MIC determination C. jejuni ATCC 33560 
Anti-
microbial 
Proportion 
outside QC 
range 
Obtained values in MIC 
steps (min/max) 
Below 
lower QC 
limit 
Above 
upper QC 
limit 
CIP 3/30 (10%) - 1 step 
ERY 0/30 (0%) - - 
GEN 5/30 (17%) 1 step - 
NAL 1/28 (4%) 1 step - 
TET 0/28 (0%) - - 
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Table 6: Results from the participation of eight laboratories in the optional genotypic characterisation component of the 
EQAS 
Test strain Expected gene Proportion of correct results (gene level) 
Proportion of correct 
results (variant level) 
Additional genes/variants 
identified 
S-8.4 
VIM-2 4/4 (100%) 3/3 (100%) CTX 
SHV TEM-1 6/6 (100%) 5/5 (100%) 
S-8.5 
CTXM-9 8/8 (100%) 7/7 (100%) 
 
TEM-1 6/6 (100%) 4/4 (100%) 
S-8.6 
CTXM-3 8/8 (100%) 5/7 (71%) CTXM-1 
CTXM-15 OXA-30 6/6 (100%) 4/4 (100%) 
S-8.7 TEM-52 8/8 (100%) 6/6 (100%) CTX 
 
4. Discussion 
It is important to consider that the number of 
EQAS participants differs from year to year, 
which implies that comparisons among different 
EQAS iterations should be interpreted with 
caution.  
The EURL-AR has emphasized the need for 
harmonization of AST methodology among 
NRLs, and has recommended MIC 
determination on several occasions. In this 
EQAS trial, the number of participants 
performing MIC determination is comparable to 
the high numbers observed last year. Moreover, 
the EU regulation specifying the AST method to 
be performed from the 2014 monitoring, refers 
to MIC testing alone. 
4.1 Salmonella trial  
Overall, the percentage of correct antimicrobial 
susceptibility test results of Salmonella was 
99.3%. The majority (n=32) of participants 
obtained satisfactory results according to the 
level of acceptance (<5% deviation).  
As indicated in Figure 2, the overall quality of 
the results in the 2013-EQAS would appear to 
be at the same level or increasing compared to 
the performance in the former iterations.  
In previous years, the testing of ciprofloxacin 
towards strains exhibiting reduced susceptibility 
to this antimicrobial and the correct 
interpretation of these results has caused 
problems to laboratories performing disk 
diffusion. This year, one laboratory obtained a 
deviation on this account when submitting a 
zone diameter of 19 mm for ciprofloxacin and 
an interpretation as susceptible (S-8.1). The 
protocol (App. 4b) refers to the CLSI 
interpretative criteria for ciprofloxacin which 
allow laboratories performing DD for AST to 
detect plasmid-mediated quinolone resistance.  
As indicated by Figure 4, deviation levels higher 
than 5% were exhibited by two laboratories 
(#42 and #58). For laboratory #42, all 
deviations were related to S-8.8 where 
resistance to five antimicrobials was expected, 
and none of these were detected. This could be 
caused by a technical error causing mix-up of 
strains in the laboratory or it could be due to the 
loss of a plasmid in the test strain. For 
laboratory #58, the seven deviations all are 
caused by detection of a high MIC-level and a 
categorization as resistant where the expected 
result was susceptible. In two of the cases, 
sulfonamides caused a high MIC which could 
be due to the bacteriostatic property of this drug 
(the MIC should be read at 80% inhibition) that 
might have caused an incorrect determination 
of the MIC. Both laboratories presenting 
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deviation levels above 5% have been contacted 
by the EURL-AR to discuss and work towards 
improving the quality of results. None of these 
laboratories were defined as outliers. 
For the E. coli reference strain, the obtained 
results were in general in agreement with the 
CLSI recommendations. Four laboratories 
performed AST on Salmonella by the use of 
disk diffusion and uploaded data for the testing 
of the reference strain with a total of three (7%) 
values out of range. For the laboratories 
performing AST on Salmonella by an MIC-
method, two laboratories observed problems 
when testing ertapenem, one indicated a value 
five steps above the QC-range. Also, two 
laboratories indicated the reading of a value for 
sulphonamides which was above the QC-limit. 
This reading of sulphonamides is known to 
cause problems and these laboratories are 
encouraged to look into whether this could be 
the reason for the high MIC-value for the QC-
strain.   
Laboratories #42, #44, #56, and #57 which had 
a deviation level above the acceptance limit in 
EQAS 2012 with values of 5.6%, 6.9%, 6.9%, 
and 6.9%, respectively, have increased their 
performance and in the 2013-iteration present a 
deviation level at 5.3%, 0% and 1.1% for #42, 
#44 and #56. Laboratory #57 did not participate 
in this year’s iteration of the Salmonella EQAS.  
ESC-producing Salmonella test strains 
ESC-producing microorganisms continue to be 
emerging worldwide. A mandatory part of this 
EQAS is to be able to detect them as this ability 
should be of a high priority for the NRLs.  
Of the four Salmonella test strains relevant for 
this component of the EQAS (S-8.4, S-8.5, S-
8.6 and S-8.7), one was a carbapenemase-
producer and three were ESBL-producing 
strains. The testing and interpretation of results 
caused difficulties especially for two strains; 1) 
For S-8.4, the test for meropenem resistance 
would be the reason to classify this strain as a 
carbapenemase-producer. The meropenem 
range in the MIC-panels used by most NRLs for 
the EQAS-test strains is too high to indicate 
resistance for this strain and disk diffusion 
interpretative criteria corresponding to the 
EUCAST MIC-cut off value are not available. 
The EURL-AR followed up on the strain 
regarding the MIC for meropenem by 
performing E-tests on a number agar sticks that 
had been stored since the production for the 
EQAS. These results indicated a lower 
expected value than the one presented in the 
database. The expected MIC value was 
therefore adjusted to 0.125 mg/L with an 
interpretation as ‘susceptible’. For these 
reasons, the evaluation of both the testing of 
meropenem and the classification as 
carbapenemase-producer was not further 
evaluated in this report. 2) For S-8.5, the 
classification in relation to ESBL-production 
referred to the EFSA technical specifications 
(EFSA, 2012) and thereby was intended to be 
based on the phenotypic analysis, only, which 
would result in a classification as ‘unusual 
phenotype’. Upon deadline, it was clear that 
many laboratories had performed further testing 
and based their submitted results as ‘ESBL-
producing’ on these. Obtained results from 
these two strains present examples of issues 
which the NRLs face when performing 
laboratory testing of ESC-producing strains and 
will be brought up for discussion in the network 
to work towards better tools for analysis and 
interpretation.  
Of the 34 laboratories which tested Salmonella, 
one (#58) submitted results which were 
incorrect for six of the eight test strains. This 
laboratory has been contacted by the EURL-AR 
to identify possible causes of this unsatisfactory 
performance and to improve the quality of 
results. 
When disregarding the results of laboratory 
#58, 94% of the ESC-classifications were in 
accordance with the expected in relation to the 
three relevant ESBL-producing strains (S-8.5, 
S-8.6, and S-8.7) from the 33 participating  
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laboratories. The six results not in concordance 
with the expected and relevant for discussion 
were caused by various problems with 
confirmatory testing causing an incorrect 
answer. These deviations were submitted by six 
different laboratories and thus do not indicate 
methodical issues at particular laboratories.  
4.2 Campylobacter trial  
For the Campylobacter component of this 
year’s EQAS, 30 laboratories submitted results 
leading to an overall percentage of correct AST 
results at 96.5%. The performance varied from 
no deviations up to 19.0% deviations, with 24 
laboratories performing satisfactorily according 
to the established acceptance ranges.  
Six laboratories (#6, #12, #22, #29, #37 and 
#44) obtained deviation levels above 5%, four 
of these were defined as outliers (#29, #37, #6, 
and #22) with deviation levels at 12.5%, 12.5%, 
14.6% and 19.0%. For none of these 
laboratories, the values obtained for the QC-
strain indicate methodical issues to be the 
reason for the obtained deviations. Of the four 
outliers, one (#6) indicated issues with reviving 
one Campylobacter strain (C-8.3) and the 
results indicate that upon subculture of the 
revived strain, a contamination was subcultured 
and tested. This laboratory in addition 
incorrectly interpreted two MIC-values 
concluding resistance where susceptible was 
the correct interpretation. Laboratory #22 
obtained three deviations when testing C-8.3 
and five incorrect interpretations when testing 
C-8.7 which indicates the testing of two other 
strains, possibly contaminants. Laboratory #29 
presents six deviations (12.5%) which do not 
exhibit an obvious pattern. This laboratory 
should follow up on these results by performing 
trouble and thereby detecting the cause of the 
deviating results. Finally, one laboratory (#37) 
indicated the use of a non-standardized method 
of the EQAS-strains due to financial constraints. 
This laboratory has confirmed that re-testing of 
some of the strains applying the standardized 
method rendered the expected results. All six 
laboratories presenting deviation levels above 
5% have been contacted by the EURL-AR to 
identify possible causes of this unsatisfactory 
performance and to improve the quality of 
results. 
All participating laboratories uploaded data from 
tests performed on the C. jejuni reference strain 
and the proportion of results within the QC 
intervals was 93.8%. The nine values outside 
the QC intervals were all just one step below or 
above the QC-limits. The laboratories obtaining 
these values should monitor these over time to 
ensure that their tests render a reliable result 
for the particular antimicrobial. 
Laboratories #36, #40, and #44 which were 
regarded as outliers in EQAS 2012 with 
deviation levels at 10.3%, 12.8%, and 15.4%, 
respectively, all increased their performance in 
the 2013-iteration and obtained deviation levels 
at 2.1%, 4.2% and 8.3%, respectively.  
 
In the present report, results from the 
Salmonella and Campylobacter EQAS 
2013 are assessed in relation to the 
database evalution and referring to the 
interpretation as susceptible or resistant as 
the reference value.  
At the annual workshops, the network has 
discussed whether this could be improved 
by instead assessing the obtained MIC-
value. The suggestion is that the reference 
value is set at the expected MIC-value +/- 
one dilution step.  
At the upcoming workshop in April 2014, 
the results presented in this report will be 
presented based on analysis according to 
this suggestion. After that it will be decided 
how to proceed to obtain the best 
evaluation of the proficiency of the NRLs in 
relation to AST-results obtained by 
microbroth dilution.  
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4.3 Genotypic characterisation 
The focus on genotypic characterization of 
microorganisms is increasing in the EU and 
worldwide. In EU, communication has been 
ongoing to improve laboratory detection and 
confirmation of ESBL- and pAmpC-producing 
Enterobacteriaceae.  
Especially, the agenda now is focused at 
carbapenemase resistant organisms, with the 
recent EFSA Scientific Opinion (EFSA BIOHAZ 
Panel, 2013) describing the importance of 
determining the identity of the genes 
responsible for the carbapenemase production 
by molecular methods.  
The optional genotypic characterisation offered 
as a supplementary part of this EQAS should 
therefore be seen as an important possibility for 
the NRL-AR’s to introduce this method in the 
laboratory and thereby be at the forefront when 
the method proposals are adopted. This year, 
eight laboratories participated in this optional 
EQAS item. 
5. Conclusions 
The goal of the EURL-AR EQAS is to have all 
participating NRLs performing antimicrobial 
susceptibility testing of Salmonella and 
Campylobacter with a deviation level below 5%. 
This seems within reach for Salmonella as well 
as for Campylobacter.  
The performance of the NRL’s appear to be at 
the same level for Salmonella AST’s in this 
EQAS (99.3%) when compared to the results 
from the EQAS 2009, 2010, 2011 and 2012 
(98.4%, 97.8%, 98.1%, and 99.0%). Regarding 
Campylobacter AST’s, the level of deviation 
appears to have risen and this year reach a 
level of 3.5% in 2013 compared to 2.2%, 2.0%, 
1.9%, and 2.1% in 2009, 2010, 2011, and 2012. 
Four laboratories were regarded as outliers for 
the Campylobacter AST (#29, #37, #6, and 
#22) due to their higher deviation levels (12.5%, 
12.5%, 14.6% and 19.0%).  
Eight NRLs participated in the EQAS 
component consisting of genotypic testing of 
ESBL-, AmpC- and carbapenemase-producing 
Enterobacteriaceae. Improvement is needed to 
correctly identify the phenotype of Salmonella 
spp. producing beta-lactamases of the ESBL-, 
AmpC, and carbepenemase-type as this is a 
priority area within the EURL-AR activities. We 
strongly encourage participants having 
problems in identifying these strains to perform 
a re-test of the test strains as a training 
exercise and to contact the EURL-AR in case 
any discussion is needed. 
Finally, the EURL-AR is open to suggestions to 
improve future EQAS trials and invites the 
entire network to contribute with ideas for 
training courses and specific focus areas to 
expand the network’s knowledge in 
antimicrobial resistance. 
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EQAS 2013  
FOR SALMONELLA, CAMPYLOBACTER AND OPTIONAL GENOTYPIC CHARACTERISATION 
The EURL-AR announces the launch of another EQAS, thus providing the opportunity for 
proficiency testing which is considered an essential tool for the generation of reliable laboratory 
results of consistently good quality. 
This EQAS consists of antimicrobial susceptibility testing of eight Salmonella isolates and eight 
Campylobacter isolates. For the optional genotypic characterisation, the ESBL-genes in the relevant 
Salmonella strains should be detected. Additionally, quality control (QC) strains E. coli ATCC 
25922 (CCM 3954) and C. jejuni ATCC 33560 (CCM 6214) will be distributed to new participants.  
This EQAS is specifically for NRL’s on antimicrobial resistance. Therefore, laboratories designated 
to be NRL-AR do not need to sign up to participate but are automatically regarded as participants. 
Participation is free of charge for all designated NRL-AR’s.  
TO AVOID DELAY IN SHIPPING THE ISOLATES TO YOUR LABORATORY 
The content of the parcel is “UN3373, Biological Substance Category B”: Eight Salmonella strains, 
eight Campylobacter and, for new participants, also the QC strains mentioned above. Please provide 
the EQAS coordinator with documents or other information that can simplify customs procedures 
(e.g. specific text that should be written on the proforma invoice). To avoid delays, we kindly ask 
you to send this information already at this stage.  
TIMELINE FOR RESULTS TO BE RETURNED TO THE NATIONAL FOOD INSTITUTE 
Shipment of isolates and protocol: The isolates will be shipped in October 2013. The protocol for 
this proficiency test will be available for download from the website (www.eurl-ar.eu).  
Submission of results
Upon reaching the deadline, each participating laboratory is kindly asked to enter the password-
protected website once again to download an automatically generated evaluation report. 
: Results must be submitted to the National Food Institute no later than 
December 6th 2013 via the password-protected website.  
EQAS report
 
: A report summarising and comparing results from all participants will be issued. In 
the report, laboratories will be presented coded, which ensures full anonymity. The EURL-AR and 
the EU Commission, only, will have access to un-coded results. The report will be publicly 
available. 
Next EQAS
Please contact me if you have comments or questions regarding the EQAS. 
: The next EURL-AR EQAS that we will have is on antimicrobial susceptibility testing 
of E. coli, staphylococci and enterococci which will be carried out in June 2014.  
Sincerely, 
 
 
Susanne Karlsmose (suska@food.dtu.dk) 
EQAS-Coordinator 
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Participant list
Salmonella Campylobacter Genotypic characterisation Institute  Country
X X - Austrian Agency for Health and Food Safety Austria
X X - Institute of Public Health Belgium
X X - Nacional Diagnostic and Research Veterinary Institute Bulgaria
X X - Croatian Veterinary Institut Croatia
X X - Veterinary Services Cyprus
X X X State Veterinary Institute Praha Czech Republic
X X X National Food Institute Denmark
X X - Estonian Veterinary and Food Laboratory Estonia
X X X Finnish Food Safety Authority EVIRA Finland
X - - Agence nationale de sécurité sanitaire ANSES - Fougères LERMVD France
X - - Agence nationale de sécurité sanitaire ANSES - LERQAP France
X - - Agence nationale de sécurité sanitaire ANSES - Lyon France
- X - Agence nationale de sécurité sanitaire ANSES - Ploufragan - LERAP France
X X X Federal Institute for Risk Assessment Germany
X - - Veterinary Laboratory of Chalkis Greece
X X - Central Agricultural Office Veterinary Diagnostic Directorate Hungary
X X - University of Iceland Iceland
X X - Central Veterinary Research Laboratory Ireland
X X X Istituto Zooprofilattico Sperimentale delle Regioni Lazio e Toscana Italy
X X - Institute of Food Safety, Animal Health and Enviroment "BIOR" Latvia
X X - National Food and Veterinary Risk Assessment Institute Lithuania
X X* - Public Health Laboratory Malta
X X X Central Veterinary Institute of Wageningen UR Netherlands
X X - Food and Consumer Product Safety Authority (VWA) Netherlands
X X - Veterinærinstituttet Norway
X X - National Veterinary Research Institute Poland
X X - Laboratorio National de Investigacáo Veterinaria Portugal
X X - Institute for Diagnosis and Animal Health Romania
X X - Institute for Hygiene and Veterinary Public Health Romania
X X - State Veterinary and Food Institute  (SVFI) Slovakia 
X X - National Veterinary Institute Slovenia
X X X Laboratorio Central de Sanidad, Animal de Algete Spain
X X - VISAVET Health Surveillance Center, Complutense University Spain
X X X National Veterinary Institute, SVA Sweden
X X - Vetsuisse Faculty Bern, Institute of Veterinary Bacteriology Switzerland
X X - Public Health England - Colindale United Kingdom
X X - The Veterinary Laboratory Agency United Kingdom
*ID of Campylobacter  species performed. AST not performed
Designated NRL-AR by the compentent authority of the member state
Non-NRL-AR enrolled by the EURL-AR
Not a Member State of the EU
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Reference values (MIC-value and interpretation) - Salmonella 
Ampicillin Cefepime Cefotaxime ESBL-confirmation Cefoxitin Ceftazidime ESBL-confirmation Chloramphenicol Ciprofloxacin
AMP FEP CTX CTX:CTX/Cl FOX CAZ CAZ:CAZ/Cl CHL CIP 
EURL S-8.1 <= 1 SUSC <= 0.12 SUSC  = 0.5 SUSC  = 8 SUSC  = 0.25 RESIST
EURL S-8.2  = 2 SUSC <= 0.12 SUSC  = 0.25 SUSC  = 8 SUSC  = 0.03 SUSC
EURL S-8.3  > 32 RESIST <= 0.12 SUSC  = 0.5 SUSC  = 8 SUSC  > 4 RESIST
EURL S-8.4  > 32 RESIST  <= 1 SUSC > 4 RESIST  ratio <8 No synergy  > 64 RESIST  = 32 RESIST ratio <8 No synergy  = 4 SUSC  > 4 RESIST
EURL S-8.5  > 32 RESIST  = 2 SUSC > 4 RESIST  ratio >8 Synergy (E-test: 
Phantom zone)
 <= 4 SUSC  = 1 SUSC ratio <8 No synergy  = 8 SUSC  = 0.5 RESIST
EURL S-8.6  > 32 RESIST  > 16 RESIST > 4 RESIST   ratio >8 Synergy  <= 4 SUSC  = 16 RESIST ratio =8 Synergy  > 64 RESIST  = 1 RESIST
EURL S-8.7  > 32 RESIST  > 16 RESIST > 4 RESIST ratio >8 Synergy (E-test: 
deformation)
 <= 4 SUSC  = 64 RESIST ratio >8 Synergy  = 8 SUSC  = 0.03 SUSC
EURL S-8.8  > 32 RESIST <= 0.12 SUSC  = 0.25 SUSC  > 64 RESIST  = 0.03 SUSC
Colistin Ertapenem Gentamicin Imipenem Meropenem Nalidixic acid Sulfamethoxazole Tetracycline Trimethoprim Relevant genes
COL ERT GEN IMI MER NAL SMX TETRA TMP
EURL S-8.1  <= 1 SUSC <= 0.5 SUSC  <= 0.03 SUSC  = 8 SUSC  <= 64 SUSC <= 2 SUSC <= 1 SUSC
EURL S-8.2  <= 1 SUSC  = 0.5 SUSC  <= 0.03 SUSC  <= 4 SUSC  <= 64 SUSC <= 2 SUSC <= 1 SUSC
EURL S-8.3  <= 1 SUSC  = 16 RESIST  <= 0.03 SUSC  > 64 RESIST  > 1024 RESIST  > 32 RESIST <= 1 SUSC
EURL S-8.4  <= 1 SUSC  = 0.25 RESIST  = 16 RESIST  = 2 RESIST  = 0.125 SUSC  > 64 RESIST  > 1024 RESIST  > 32 RESIST <= 1 SUSC TEM-1; VIM-2
EURL S-8.5  <= 1 SUSC  = 0.016 SUSC <= 0.5 SUSC <= 0.5 SUSC  <= 0.03 SUSC  > 64 RESIST  <= 64 SUSC  > 32 RESIST <= 1 SUSC TEM-1, CTXM-9
EURL S-8.6  <= 1 SUSC  = 0.06 SUSC  > 16 RESIST <= 0.5 SUSC  = 0.06 SUSC  > 64 RESIST  > 1024 RESIST  > 32 RESIST  > 32 RESIST CTX M-3; OXA-30
EURL S-8.7  <= 1 SUSC  = 0.03 SUSC <= 0.5 SUSC <= 0.5 SUSC  = 0.06 SUSC  <= 4 SUSC  <= 64 SUSC <= 2 SUSC <= 1 SUSC TEM-52
EURL S-8.8  <= 1 SUSC <= 0.5 SUSC  <= 0.03 SUSC  <= 4 SUSC  > 1024 RESIST  > 32 RESIST  > 32 RESIST
Resistant
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Ciprofloxacin Erythromycin Gentamicin Nalidixic acid Streptomycin Tetracycline
Species Code CIP ERY GEN NAL STR TET
C. coli EURL C-8.1 > 4 RESIST  > 32 RESIST  = 0.5 SUSC  > 64 RESIST  > 16 RESIST  = 8 RESIST
C. coli EURL C-8.2  = 0.12 SUSC  > 32 RESIST  = 0.5 SUSC  = 8 SUSC  = 2 SUSC  = 1 SUSC
C. jejuni EURL C-8.3 > 4 RESIST  = 2 SUSC  = 0.25 SUSC  > 64 RESIST  <= 1 SUSC  > 16 RESIST
C. jejuni EURL C-8.4  = 0.5 SUSC  = 1 SUSC  = 0.25 SUSC  = 64 RESIST  <= 1 SUSC  > 16 RESIST
C. jejuni EURL C-8.5  > 4 RESIST  = 2 SUSC  = 0.5 SUSC  > 64 RESIST  = 2 SUSC  = 0.25 SUSC
C. coli EURL C-8.6  = 0.25 SUSC  = 4 SUSC  = 0.5 SUSC  = 16 SUSC  > 16 RESIST  > 16 RESIST
C. coli EURL C-8.7  = 0.06 SUSC  = 1 SUSC  = 0.25 SUSC  = 4 SUSC  <= 1 SUSC  = 0.5 SUSC
C. coli EURL C-8.8  > 4 RESIST  = 0.5 SUSC  = 0.25 SUSC  = 64 RESIST  > 16 RESIST  > 16 RESIST
Resistant
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EURL-AR External Quality Assurance System 2013 
- Salmonella, Campylobacter and optional genotypic characterisation 
 
Id: «Lab_no_» 
«Name» 
«Institute__» 
«Country» 
Kgs. Lyngby, October 2013 
 
Dear «Name», 
 
Please find enclosed the bacterial strains for the EURL-AR EQAS 2013. Upon arrival to your 
laboratory, the strains should be stored dark and at 4°C for stabs, and dark and cool for freeze-
dried strains. Charcoal swabs must be subcultured straight away.  
 
On the EURL-AR-website (www.eurl-ar.eu) the following documents relevant for the EURL-AR 
EQAS are available: 
- Protocol for Salmonella and Campylobacter including test forms 
- Instructions for Opening and Reviving Lyophilised Cultures 
- Subculture and Maintenance of Quality Control Strains 
 
We ask you to examine the eight Salmonella and the eight Campylobacter strains that we sent to 
you by performing antimicrobial susceptibility testing. The ESBL-producing Salmonella strains 
should be characterised genotypically (optional) according to the description in the protocol. In the 
protocol you can find detailed description of the procedures to follow. Additionally, you can find a 
description of the procedure to enter your results into the interactive web database. For accessing 
the database, you need this username and password. 
 
 
Your username: «Username» 
 
Your password: «Password» 
 
Please keep this document 
  Your username and password will not appear in other documents 
 
 
Results should be submitted to the database no later than December 6th
 
 2013. 
Please acknowledge receipt of this parcel immediately upon arrival (to suska@food.dtu.dk).  
Do not hesitate to contact us for further information. 
 
Yours sincerely, 
 
Susanne Karlsmose 
EQAS-Coordinator 
EU Reference Laboratory for Antimicrobial Resistance  
External Quality Assurance System (EQAS) 2013 
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PROTOCOL  
For antimicrobial susceptibility testing of Salmonella, Campylobacter and optional 
genotypic characterisation of ESBL- and carbapenemase-producing test strains 
 
1 INTRODUCTION    ..................................................................................................................... 1
2 OBJECTIVES    ............................................................................................................................ 2
3 OUTLINE OF THE EQAS 2013    .............................................................................................. 2
3.1    Shipping, receipt and storage of strains    ........................................................................ 2
3.2 Suggested procedure for reconstitution of the lyophilised reference strains    ............ 2
3.3 Susceptibility testing    ....................................................................................................... 2
3.4 Optional genotypic characterisation    ............................................................................. 6
4 REPORTING OF RESULTS AND EVALUATION    .............................................................. 6
5 HOW TO ENTER RESULTS IN THE INTERACTIVE DATABASE    ................................ 7
 
1 INTRODUCTION 
One of the tasks as the EU Reference Laboratory for Antimicrobial Resistance (EURL-AR) is to 
organise and conduct an External Quality Assurance System (EQAS) on antimicrobial susceptibility 
testing (AST) of Salmonella and Campylobacter. The Salmonella and Campylobacter EQAS 2013 
will include susceptibility testing of eight Salmonella and eight Campylobacter strains together with 
susceptibility testing of the reference strains E. coli ATCC 25922 (CCM 3954) and C. jejuni ATCC 
33560 (CCM 6214). As part of the AST of the Campylobacter, species identification of the test 
strains must be performed. Additionally, optional characterization of genes conferring ESBL-
production in the Salmonella test strains is offered. 
For new participants of the EQAS who have not already received the mentioned reference strains, 
these are included in the parcel. The reference strains will not be included in the years to come. The 
reference strains are original certified cultures and are free of charge. Please take proper care of the 
strains. Handle and maintain them as suggested in the manual ‘Subculture and Maintenance of QC 
Strains’. Please use them for future internal quality control for susceptibility testing in your 
laboratory.  
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For this EQAS, members of the Food- and Waterborne Diseases and Zoonoses Programme (FWD) 
based at ECDC are also participating, however, for these participants the EQAS has been slightly 
adjusted. Description of this can be found in this protocol, i.e. that for antimicrobial susceptibility 
testing (AST) of Campylobacter, results obtained by disk diffusion or E-test are also accepted. 
Various aspects of the proficiency test scheme may from time to time be subcontracted. When 
subcontracting occurs it is placed with a competent subcontractor and the National Food Institute is 
responsible to the scheme participants for the subcontractor’s work. 
2 OBJECTIVES 
The main objective of this EQAS is to support laboratories to assess and if necessary improve the 
quality of susceptibility testing of pathogens originating from food and animal sources, especially 
Salmonella and Campylobacter. Furthermore, to assess and improve the comparability of 
surveillance and antimicrobial susceptibility data reported to EFSA by different laboratories on 
Salmonella and Campylobacter and to harmonise the interpretative criteria used within the EU. 
3 OUTLINE OF THE EQAS 2013 
3.1    Shipping, receipt and storage of strains 
In October 2013, the EU appointed National Reference Laboratories will receive a parcel from the 
National Food Institute containing eight Salmonella and eight Campylobacter strains. QC reference 
strains will be included for participants who have not previously received these. Some of the 
Salmonella test strains are ESBL- or carbapenemase producing and are included as test strains in 
the optional EQAS-item, consisting of characterization of genes conferring ESBL- or 
carbapenemase production.  
The reference strains are shipped lyophilised, the Campylobacter test strains are shipped as a 
charcoal swabs and the Salmonella test strains are stab cultures. On arrival, the stab cultures and the 
charcoal swabs must be subcultured, and all cultures should be adequately stored until testing. A 
suggested procedure for reconstitution of the lyophilised reference strains is presented below. 
 
3.2 Suggested procedure for reconstitution of the lyophilised reference strains  
Please see the document ‘Instructions for opening and reviving lyophilised cultures’ on the EURL-
AR-website (see www.eurl-ar.eu).  
 
3.3 Susceptibility testing 
The strains should be susceptibility tested towards as many as possible of the antimicrobials listed 
in Tables 1 and 2, by the method used in the laboratory when performing monitoring for EFSA. 
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Laboratories from the FWD-network should use their routine method for testing the bacterial 
strains. 
The expected interpretation is based on MIC-values according to the interpretative criteria listed in 
Tables 1 and 2. Please note that if applying a method for susceptibility testing that does not render 
an MIC-value for interpretation by the given cut-off values, the interpretation may not correspond 
to the expected result, even if the analysis is correctly performed. This consideration should be 
included in the self-evaluation performed subsequent to the disclosure of the expected results. 
With regard to MIC range and/or disk content we ask you to fill in these pieces of information in 
the database. Also, if you do not use the cut-off values listed in the protocol for interpretation of the 
susceptibility results, please fill in or update this information in the database. 
Interpretation of obtained MIC-values or disk diffusion zone diameters
For the interpretation of obtained MIC-values, the cut off values listed in Tables 1 and 2 should be 
applied. The epidemiological cut-off values allow two categories of characterisation – resistant or 
sensitive. The cut off values used in the interpretation of the MIC results are developed by 
EUCAST (
: Interpretations in 
concordance with the expected will be categorized as ‘correct’, whereas interpretations that deviate 
from the expected will be categorized as ‘incorrect’. Note: A categorization as intermediary is not 
accepted. 
www.eucast.org). 
For the interpretation of obtained disk diffusion zone diameters, the interpretative criteria should 
correspond to those listed in Tables 1 and 2, categorising the results into the terms resistant and 
susceptible.  
 
3.3.1 Salmonella. 
The interpretative criteria that should be applied for categorizing the Salmonella test strain as 
resistant or susceptible are those listed in Tables 1 and 2.  
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Table 1: Interpretative criteria for the AST results for Salmonella spp.  
Antimicrobial MIC (µg/mL) (R>) DD (zone mm) (R<) 
Ampicillin (AMP) 8 14 
Cefotaxime (CTX) 0.5 20 
Ceftazidime (CAZ) 2 NA* 
Chloramphenicol (CHL) 16 13** 
Ciprofloxacin (CIP) 0.06 31** 
Colistin (COL) 2 NA* 
Gentamicin (GEN) 2 NA* 
Meropenem (MER) 0.125 NA* 
Nalidixic acid (NAL) 16 16 
Sulfonamides (SMX) 256*** 17** 
Tetracycline (TET) 8 12** 
Trimethoprim (TMP) 2 NA* 
* Not available from EUCAST 
** the DD zone diameter corresponding to the MIC-value (reference: CLSI M100-S23 Table 2A); note: for 
some of these, results which according to the CLSI document would be interpreted as ‘intermediary’, should 
be categorized as resistant in this proficiency test 
*** CLSI M100 Table 2A 
 
When performing antimicrobial susceptibility testing of the Salmonella test strains, the 
interpretative criteria listed in Table 1 for results obtained by MIC-determination detect plasmid 
mediated quinolone resistant test strains. When interpreting a disk diffusion result, reference should 
be made to the CLSI interpretative criteria as indicated in Table 1.  
Plasmid-mediated quinolone resistance  
Confirmatory tests for ESBL- or carbapenemase production are mandatory on all strains resistant 
to cefotaxime (CTX), ceftazidime (CAZ) or meropenem (MER).  
Extended-beta-lactam- and carbapenem resistance  
Confirmatory tests for ESBL production require the use of both cefotaxime (CTX) and ceftazidime 
(CAZ) alone and in combination with a β-lactamase inhibitor (clavulanic acid). Synergy is defined 
either as i) a ≥ 3 twofold concentration decrease in an MIC for either antimicrobial agent tested in 
combination with clavulanic acid vs. its MIC when tested alone (three dilution steps difference; 
CTX : CTX/CL or CAZ : CAZ/CL ratio ≥ 8) or ii) a ≥ 5 mm increase in a zone diameter for either 
antimicrobial agent tested in combination with clavulanic acid vs. its zone when tested alone (CLSI 
M100 Table 2A; Enterobacteriaceae). The presence of synergy indicates ESBL production. 
Resistance to cefepime gives further indication of ESBL production. Confirmatory test for 
carbapenemase production requires the testing of meropenem (MER).  
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Detection of AmpC-type beta-lactamases can be performed by testing the bacterium for 
susceptibility to cefoxitin (FOX). Resistance to FOX could indicate the presence of an AmpC-type 
beta-lactamase, that may be verified by PCR and sequencing.  
The classification of the phenotypic results should be based on the most recent EFSA 
recommendations (EFSA 20121
• Presumptive ESBL: strains with positive synergy test, susceptible to cefoxitin and 
resistant to cefepime  
) and indicated as:  
• Presumptive ESBL+pAmpC: strains with positive or negative synergy test, resistant to 
cefoxitin and resistant to cefepime  
• Presumptive pAmpC phenotype: strains with negative synergy test  
• Presumptive carbapenemase phenotype: strain resistant to meropenem  
• Unusual phenotype: any other combinations  
MIC values and relative interpretation of cefotaxime, ceftazidime and meropenem used for 
detection of beta-lactamase- and carbapenemase producing strains in this EQAS should be reported 
as found.  
 
3.3.2 Campylobacter   
For AST of Campylobacter, MIC methods should be applied, i.e. broth or agar dilution methods 
using incubation at 36-37ºC for 48 hours or 42ºC for 24 hours. Laboratories in the EURL-AR 
network must use one of these methods. For the laboratories of the FWD-network, results of AST 
of Campylobacter may be obtained by disk diffusion or in-house E-test-method.  
Table 2: Interpretative criteria for the AST results for Campylobacter jejuni and C. coli 
Antimicrobial 
C. jejuni C. coli 
MIC (µg/mL) 
(R>) 
DD (zone mm) 
(R<) 
MIC (µg/mL) 
(R>) 
DD (zone mm) 
(R<) 
Ciprofloxacin (CIP) 0.5 26 0.5 26 
Erythromycin (ERY) 4 22 8 24 
Gentamicin (GEN) 2 NA* 2 NA* 
Nalidixic acid (NAL) 16 NA* 16 NA* 
Streptomycin (STR) 4 NA* 4 NA* 
Tetracycline (TET) 1 30 2 30 
* Not available from EUCAST 
                                                          
1 European Food Safety Authority; Technical specifications on the harmonised monitoring and reporting of 
antimicrobial resistance in Salmonella, Campylobacter and indicator Escherichia coli and Enterococcus spp. bacteria 
transmitted through food. EFSA Journal 2012; 10(6):2742. [64 pp.] doi:10.2903/j.efsa.2012.2742. Available online:  
www.efsa.europa.eu/efsajournal  
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Species identification of the Campylobacter test strains must be performed. For this purpose, the 
protocol available on the EURL-AR website (
Identification of Campylobacter species 
http://eurl-ar.eu/233-protocols.htm) or in-house 
methods may be adopted. 
 
3.4 Optional genotypic characterisation 
For the optional genotypic characterisation of the ESBL-producing Salmonella test strains, the 
requested results are the genes conferring ESBL-production harboured in the test strains. The genes 
included in the test are the following: ACC, ACT, CMY, CTX, DHA, FOX, GES, IMP, KPC, 
MOX, NDM, OXA, PER, SHV, TEM, VEB, and VIM. The database lists the relevant variants of 
the genes.  
When uploading the results in the database, the identified genes will be evaluated against the 
expected results. The results will be evaluated on the detected gene (ACC-, ACT-, CMY-, etc.) as 
well as the variant identified.  
The method used for the genotypic characterisation should be your laboratory’s routine method. 
The expected results listed in the database are those obtained by the EURL-AR.  
 
4 REPORTING OF RESULTS AND EVALUATION 
Test forms are available for recording your results before you enter them into the interactive web 
database. We kindly ask you to report in the database the tested MIC range and/or antimicrobial 
disk content. If you did not 
We recommend reading carefully the description reported in paragraph 5 before entering your 
results in the web database.  Results must be submitted no later than December 6th, 2013. 
use the cut-off values recommended in the protocol for 
interpretation of AST results, please report the interpretative criteria applied. 
After 
the deadline, the database will be closed and you will be able to view and print an automatically 
generated report evaluating your results.
If you do not have access to the Internet, or if you experience difficulties in entering your results, 
try a few days later or, alternatively, return the completed test forms by e-mail, fax or mail to the 
National Food Institute, Denmark.  
 Results in agreement with the expected interpretation are 
categorised as ‘correct’, while results deviating from the expected interpretation are categorised as 
‘incorrect’. 
All results will be summarised in reports available to all participants. The data will be collected in 
an overall summary report in which anonymous laboratory results will be analyzed. This summary 
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report will focus on comparing the results from the EURL-AR network, and public health 
laboratories (FWD-laboratories) to assess the level of harmonization need.    
In addition, separate reports for the EURL-AR network (by DTU) and for public health laboratories 
(by ECDC) will be prepared.  
The data in the report will be presented with laboratory codes. A laboratory code is only known to 
the individual laboratory, while the complete list of laboratories and their respective codes is 
confidential and only known to the EURL-AR (all participants), the ECDC (FWD-laboratories) and 
the EU Commission (NRL-ARs). All conclusions and all three reports will be publicly available.  
If you have any questions, please do not hesitate to contact the EQAS Coordinator: 
Susanne Karlsmose 
National Food Institute 
Technical University of Denmark 
Kemitorvet, Building 204, DK-2800 Lyngby 
Denmark 
Tel: +45 3588 6601 
Fax: +45 3588 6341 
E-mail: suska@food.dtu.dk 
 
5 HOW TO ENTER RESULTS IN THE INTERACTIVE DATABASE 
Please read this passage before entering the web page. Before you go ahead, you need your test 
form by your side together with your breakpoint values.  
You are able to browse back and forth by using the forward and back keys or click on the EURL 
logo. 
You enter the EURL-AR EQAS 2013 web page (http://thor.dfvf.dk/crl) then write your username 
and password in low cases and press enter. Your username and password is the same as in the 
previous EQAS’s arranged by the National Food Institute. If you have problems with the login 
please contact us. 
Click on either “Salmonella test results” or “Campylobacter test results” depending on your results. 
The below description is aimed at Salmonella entry but is the same for Campylobacter entry. 
Click on "Start of Data Entry - Methods and Breakpoints for Salm.” 
In the next page you navigate to fields with the Tab-key and mouse.  
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Fill in what kind of method you have used for the susceptibility testing of Salmonella and the brand 
of discs, tablets, MIC trays etc.  
Fill in the relevant information, either disk content or MIC range. If you use disk diffusion, please 
upload the breakpoints used. 
You will find one more box to fill in on this page when testing Campylobacter: Fill in the actual 
incubation condition used for susceptibility testing of Campylobacter – 36°C/48h or 42°C/24h. 
Click on "save and go to next page”  
In the data entry pages for each Salmonella and Campylobacter strain, you enter the species (for 
Campylobacter only), the obtained value and the interpretation as R or S. 
For Salmonella, you also type in results for the ESBL tests. 
If you have not used an antimicrobial, please leave the field empty. 
Click on "save and go to next page" 
When uploading data on the reference strains please enter the zonediameters in mm or MIC values 
in µg/ml. Remember to use the operator keys to show e.g. equal to, etc. If you do not use CLSI 
guidelines for AST on the reference strains, please add a comment on the method used. 
Click on "save and go to next page" 
This page is a menu, from where you can review the input pages, approve your input and finally see 
and print the submitted results: 
Browse through the pages and make corrections if necessary. Remember to save a page if you make 
any corrections. If you save a page without changes, you will see an error screen, and you just have 
to click on "back" to get back to the page and "go to next page" to continue. 
Please fill in the evaluation form. 
Approve your input. Be sure that you have filled in all the results before approval, as  YOU CAN 
ONLY APPROVE ONCE!  The approval blocks your data entry in the interactive database, but 
allows you to see the evaluated results.   
If you have performed the optional genotypic characterisation: 
Click on “Gene test” and follow the description in the database for upload of the results of the 
optional genotypic characterization. Approve your input. Be sure that you have filled in all the 
results before approval. The approval blocks your data entry in the interactive database, but allows 
you to see the submitted results. 
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Salmonella, Campylobacter and genetic characterisation 
 
TEST FORMS 
   
 
 
Name:       
 
Name of laboratory:       
 
Name of institute:       
 
City:       
 
Country:       
 
E-mail:       
 
Fax:       
 
 
Comments:       
EU Reference Laboratory for Antimicrobial Resistance  
External Quality Assurance System (EQAS) 2013 
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TEST FORM                                                            
 
Does your laboratory have an accreditation for Salmonella AST?   Yes     No 
 
Does your laboratory have an accreditation for other laboratory methods/tests?   Yes    No 
 
Which method did you use for antimicrobial susceptibility testing of Salmonella in this EQAS: 
  Broth Microdilution    
  Agar dilution 
  E-test (strips)                                       
  Disk diffusion (paper disks)  
  Rosco Neo Sensitabs (tablets)            
 
Brand of microdilution plate, strips or disks:       
 
Method used for detection of ESBL-producing strains, see pictures of the methods on 
http://www.eurl-ar.eu/201-resources.htm  
 
  E-test 
  Double disk 
  Combination disk                                       
  MIC determination (microbroth)  
  Selective media please specify:       
  Other, please specify        
 
Comments or additional information:       
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TEST FORM          
 
Breakpoints used (zonediameters) and general info regarding disk content and test-range 
used for MIC: 
 
- Please fill in the disk content or the test-range used for MIC, respectively. 
- Please, only fill in breakpoints if you did not use a MIC method, that is, only if you used other 
breakpoints/cut-off values than the ones listed in the protocol for interpretation of AST results for 
Salmonella. Otherwise leave breakpoint fields empty. 
                                                   
 
 
 
 
Antimicrobial  General info 
 
The relevant information in the 
two columns below should be 
filled in 
 
Zonediameter (mm) 
 
Please, only fill in breakpoint information if 
you did not use the cut-off values listed in 
the protocol  
 
Disk content 
(μg) 
Test-range for 
MIC 
(μg/mL) 
Resistant 
(mm) 
Intermediate 
(mm) 
Sensitive 
(mm) 
 
Ampicillin, AMP             ≤             ≥       
Cefotaxime, CTX             ≤             ≥       
Ceftazidime, CAZ             ≤             ≥       
Chloramphenicol, CHL             ≤             ≥       
Ciprofloxacin, CIP             ≤             ≥       
Colistin, COL             ≤             ≥       
Gentamicin, GEN             ≤             ≥       
Meropenem, MER             ≤             ≥       
Nalidixic acid, NAL             ≤             ≥       
Sulfamethoxazole, SMX             ≤             ≥       
Tetracycline, TET             ≤             ≥       
Trimethoprim, TMP               ≤             ≥       
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TEST FORM                                                            
 
Does your laboratory have an accreditation for Campylobacter AST?  Yes     No 
 
Does your laboratory have an accreditation for other laboratory methods/tests?  Yes     No 
 
Incubation conditions:     36-37ºC / 48h   42ºC / 24h 
 
Method used for antimicrobial susceptibility testing of Campylobacter in this EQAS:: 
 Microbroth 
 Agardilution 
 Disk diffusion 
 In-house (E-test) 
 
Brand of broth/agar:       
Additional comments:       
 
How many Campylobacter isolates does your laboratory annually isolate:       
How many Campylobacter isolates does your laboratory annually susceptibility test:       
 
If using disk diffusion test or an in-house method (E-test), 
- Please fill in the disk content or the test-range used for E-test, respectively. 
- Please fill in interpretative criteria if you used other breakpoints/cut-off values than the ones listed 
in the protocol for interpretation of AST results for Campylobacter. Otherwise leave breakpoint 
fields empty. 
 
 
Antimicrobial  General info 
 
The relevant information in the 
two columns below should be 
filled in 
 
Zonediameter (mm) 
 
Please, only fill in breakpoint information if 
you did not use the cut-off values listed in 
the protocol  
 
Disk content 
(μg) 
Test-range for 
MIC 
(μg/mL) 
Resistant 
(mm) 
Intermediate 
(mm) 
Sensitive 
(mm) 
 
Ciprofloxacin             ≤             ≥       
Erythromycin             ≤             ≥       
Gentamicin             ≤             ≥       
Nalidixic Acid             ≤             ≥       
Streptomycin             ≤             ≥       
Tetracycline             ≤             ≥       
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TEST FORM  
Strain  
 
 
Antimicrobial  
Interpretation 
≤ 
> 
Zonediam (mm) or 
MIC-value (μg/ml) 
S / R 
Salmonella 
EURL S. 8.X 
 
Ampicillin, AMP                   
Cefotaxime, CTX                   
Ceftazidime, CAZ                   
Chloramphenicol, CHL                   
Ciprofloxacin, CIP                   
Colistin, COL                   
Gentamicin, GEN                   
Meropenem, MER                   
Nalidixic acid, NAL                   
Sulfonamides, SMX                   
Tetracycline, TET                   
Trimethoprim, TMP                   
 
All strains resistant to cefotaxime (CTX), ceftazidime (CAZ) or meropenem (MER) should be 
included for confirmatory tests for ESBL or carbapenemase production. See further description of 
confirmatory tests in the protocol section ‘3.3.1 Salmonella’. 
 MIC, value or ratio  Disks, zone diameter or increase 
CTX/CL : CTX MIC ratio    
 MIC ratio ≥ 8 (synergy) 
 MIC ratio < 8 
 Phantom zone (synergy) 
 Deformation (synergy) 
 Not determinable 
 Incr. in zone diam   
 Incr. ≥ 5 mm (synergy) 
 Incr.< 5 mm 
 
CAZ/CL : CAZ MIC ratio  
 MIC ratio ≥ 8 (synergy) 
 MIC ratio < 8 
 Phantom zone (synergy) 
 Deformation (synergy) 
 Not determinable 
 Incr. in zone diam  
 Incr. ≥ 5 mm (synergy) 
 Incr.< 5 mm 
 
Cefoxitin, FOX MIC value   MIC value > 8   MIC value ≤ 8  Zone diameter  
 D < 18 mm  
 D ≥ 18 mm 
Cefepime, FEP MIC value  MIC value > 8  MIC value ≤ 8  Zone diameter  
 D < 18 mm  
 D ≥ 18 mm 
Imipenem, IMI MIC value   MIC value > 1   MIC value ≤ 1  Zone diameter  
 D < 23 mm  
 D ≥ 23 mm 
Ertapenem, ERP MIC 
value  
 MIC value > 0.06 
 MIC value ≤ 0.06  Zone diameter  
 D < 22mm  
 D ≥ 22 mm 
 Presumptive  ESBL 
 
 Presumptive ESBL+ pAmpC 
 Presumptive pAmpC 
 
 Presumptive carbapenemase 
 Unusual phenotype  
 
 Not ESBL-producing 
Comments (include genotype or other results):       
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TEST FORM                                                            
 
Susceptibility testing of E. coli reference strain ATCC 25922 
 
Strain 
 
 
 
Antimicrobial  
 
Zonediameter (mm) or  
MIC-value (μg/ml) 
E. coli ATCC 25922 
 
 
 
 
Ampicillin, AMP       
Cefepime, FEP       
Cefotaxime, CTX       
Cefoxitin, FOX       
Ceftazidime, CAZ       
Chloramphenicol, CHL       
Ciprofloxacin, CIP       
Colistin, COL       
Ertapenem, ERP       
Gentamicin, GEN       
Imipenem, IMI       
Meropenem, MER       
Nalidixic acid, NAL       
Sulfisoxazole, FIS*       
Tetracycline, TET       
Trimethoprim, TMP       
 
*The antimicrobial which is mentioned in the CLSI M100 performance standard as a representative 
for the sulfonamides as regards acceptable limits for quality control strains (CLSI M100, Table 3) 
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TEST FORM                                                           
Strain Antimicrobial  Interpretation 
MIC-value (μg/ml) S / R 
Campylobacter 
EURL C. 8.1 
 
     C. jejuni 
 
     C. coli 
Ciprofloxacin             
Erythromycin             
Gentamicin             
Nalidixic Acid             
Streptomycin             
Tetracycline             
Campylobacter 
EURL C. 8.2 
 
     C. jejuni 
 
     C. coli 
Ciprofloxacin             
Erythromycin             
Gentamicin             
Nalidixic Acid             
Streptomycin             
Tetracycline             
Campylobacter 
EURL C. 8.3 
 
     C. jejuni 
 
     C. coli 
Ciprofloxacin             
Erythromycin             
Gentamicin             
Nalidixic Acid             
Streptomycin             
Tetracycline             
Campylobacter 
EURL C. 8.4 
 
     C. jejuni 
 
     C. coli 
Ciprofloxacin             
Erythromycin             
Gentamicin             
Nalidixic Acid             
Streptomycin             
Tetracycline             
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TEST FORM                                                           
 
Susceptibility testing of Campylobacter jejuni reference strain ATCC 33560 
 
Strain 
 
 
 
Antimicrobial  
 
MIC-value (μg/ml) 
36 °C/48 hours 
 
42 °C/24 hours 
 
 
C. jejuni ATCC 33560 
 
Ciprofloxacin             
Erythromycin             
Gentamicin             
Nalidixic Acid             
Tetracycline             
 
 
  
 
 
 
 
 
 
 
 
 
 
  
EU Reference Laboratory for Antimicrobial Resistance  
External Quality Assurance System (EQAS) 2013 
 
Appendix 4c, page 9 of 9 
 
Page 9 of 9 
M00-06-001/11.10.2013_version2 
Udskrevet d.: 18-02-2014 
TEST FORM – genotypic characterisation                                                           
 
Genotypic characterisation of the test strains 
 
Strain code:  
      
Method used:        
If PCR-methods, additional information should be given below 
 
Gene:       
 
 Found 
 Tested, not found 
 Published method , reference:       
 In-house method 
Primer used 5’→3’:       
Primer used 3’→5’:       
 
Gene:       
 
 Found 
 Tested, not found 
 Published method , reference:       
 In-house method 
Primer used 5’→3’:       
Primer used 3’→5’:       
 
Gene:       
 
 Found 
 Tested, not found 
 Published method , reference:       
 In-house method 
Primer used 5’→3’:       
Primer used 3’→5’:       
 
Gene:       
 
 Found 
 Tested, not found 
 Published method , reference:       
 In-house method 
Primer used 5’→3’:       
Primer used 3’→5’:       
 
Gene:       
 
 Found 
 Tested, not found 
 Published method , reference:       
 In-house method 
Primer used 5’→3’:       
Primer used 3’→5’:       
 
Comments:       
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INSTRUCTIONS FOR OPENING AND REVIVING 
LYOPHILISED CULTURES 
 
 
Manual from  Czech Collection of Microorganisms (CCM) 
 Masaryk University 
 Tvrdého 14 
 602 00 BRNO 
 Czech Republic 
 
Lyophilised cultures are supplied in vacuum-sealed ampoules. Care should be taken in opening the 
ampoule. All instructions given below should be followed closely to ensure the safety of the person 
who opens the ampoule and to prevent contamination of the culture. 
a. Check the number of the culture on the label inside the ampoule 
b. Make a file cut on the ampoule near the middle of the plug 
c. Disinfect the ampoule with alcohol-dampened gauze or alcohol-dampened cotton wool from 
just below the plug to the pointed end 
d. Apply a red-hot glass rod to the file cut to crack the glass and allow air to enter slowly into 
the ampoule 
e. Remove the pointed end of the ampoule into disinfectant 
f. Add about 0.3 ml appropriate broth to the dried suspension using a sterile Pasteur pipette 
and mix carefully to avoid creating aerosols. Transfer the contents to one or more suitable 
solid and /or liquid media 
g. Incubate the inoculated medium at appropriate conditions for several days 
h. Autoclave or disinfect effectively the used Pasteur pipette, the plug and all the remains of 
the original ampoule before discarding 
Please note that:  
 Cultures should be grown on media and under conditions as recommended in the CCM 
catalogue 
 Cultures may need at least one subculturing before they can be optimally used in experiments 
 Unopened ampoules should be kept in a dark and cool place! 
Appendix 4d, page 1 of 1
EU Reference Laboratory for Antimicrobial Resistance  
External Quality Assurance System (EQAS)  
 
 
Subculture and Maintenance of QC strains                                                                              DFVF-M00-06-001/01.09.2011 
 
Page 1 of 4 
 
SUBCULTURE AND MAINTENANCE OF    
QUALITY CONTROL STRAINS 
1.1 Purpose 
Improper storage and repeated subculturing of bacteria can produce alterations in antimicrobial 
susceptibility test results. The Clinical and Laboratory Standards Institute (CLSI, formerly NCCLS) 
has published a guideline for Quality Control (QC) stock culture maintenance to ensure consistent 
antimicrobial susceptibility test results. 
1.2 References 
M100-S21, January 2011 (Performance Standards for Antimicrobial Susceptibility Testing) 
M7-A8, January 2009 (Methods for Dilution Antimicrobial Susceptibility Test for Bacteria That 
Grow Aerobically; Approved Standard) 
1.3 Definition of Terms 
Reference Culture: A reference culture is a microorganism preparation that is acquired from a 
culture type collection.  
Reference Stock Culture: A reference stock culture is a microorganism preparation that is derived 
from a reference culture. Guidelines and standards outline how reference stock cultures must be 
processed and stored.  
Working Stock Cultures: A working stock culture is growth derived from a reference stock culture. 
Guidelines and standards outline how working stock cultures must be processed and how often they 
can be subcultured.  
Subcultures (Passages): A subculture is simply the transfer of established microorganism growth on 
media to fresh media. The subsequent growth on the fresh media constitutes a subculture or 
passage. Growing a reference culture or reference stock culture from its preserved status (frozen or 
lyophilized) is not a subculture. The preserved microorganism is not in a stage of established 
growth until it is thawed or hydrated and grown for the first time 
1.4 Important Considerations 
 Do not use disc diffusion strains for MIC determination. 
 Obtain QC strains from a reliable source such as ATCC 
 CLSI requires that QC be performed either on the same day or weekly (only after 30 day QC 
validation) 
 Any changes in materials or procedure must be validated with QC before implemented 
 For example: Agar and broth methods may give different QC ranges for drugs such as 
glycopeptides, aminoglycosides and macrolides 
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 Periodically perform colony counts to check the inoculum preparation procedure 
 Ideally, test values should be in the middle of the acceptable range 
 Graphing QC data points over time can help identify changes in data helpful for 
troubleshooting problems 
1.5 Storage of Reference Strains 
Preparation of stock cultures 
 Use a suitable stabilizer such as 50% fetal calf serum in broth, 10-15% glycerol in tryptic 
soy broth, defibrinated sheep blood or skim milk to prepare multiple aliquots. 
 Store at -20°C, -70°C or liquid nitrogen. (Alternatively, freeze dry.) 
 Before using rejuvenated strains for QC, subculture to check for purity and viability. 
Working cultures 
 Set up on agar slants with appropriate medium, store at 4-8°C and subculture weekly. 
 Replace the working strain with a stock culture at least monthly. 
 If a change in the organisms inherent susceptibility occurs, obtain a fresh stock culture or a 
new strain from a reference culture collection e.g. ATCC. 
1.6 Frequency of Testing 
Weekly vs. daily testing  
Weekly testing is possible if the lab can demonstrate satisfactory performance with daily testing as 
follows: 
 Documentation showing reference strain results from 30 consecutive test days were within 
the acceptable range. 
 For each antimicrobial/organism combination, no more than 3 out of 30 MIC values may be 
outside the acceptable range. 
When the above are fulfilled, each quality control strain may be tested once a week and whenever 
any reagent component is changed. 
Corrective Actions  
If an MIC is outside the range in weekly testing, corrective action is required as follows: 
 Repeat the test if there is an obvious error e.g. wrong strain or incubation conditions used 
 If there is no obvious error, return to daily control testing 
The problem is considered resolved only after the reference strain is tested for 5 consecutive days 
and each drug/organism result is within specification on each day. 
If the problem cannot be resolved, continue daily testing until the errors are identified. 
Repeat the 30 days validation before resuming weekly testing. 
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DAILY MIC QC CHART 
 
Reference: CLSI M7-A8, page 44 
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WEEKLY MIC QC CHART 
 
 
Reference: CLSI M7-A8, page 45 
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Quality Control ranges for ATCC reference strains
Antimicrobial
Ampicillin, AMP
Cefepime, FEP
Cefotaxime, CTX
Ceftazidime, CAZ
Chloramphenicol, CHL
Ciprofloxacin, CIP
Colistin, COL
Ertapenem, ERTA
Gentamicin, GEN
Imipenem, IMI
Meropenem, MERO
Nalidixic acid, NAL
Sulfisoxazole, FIS
Tetracycline, TET
Trimethoprim, TMP
Antimicrobial Microbroth                
(36-37°C/48h)
Microbroth 
(42°C/24h)
Agar dilution     
(36-37°C/48h)
Agar dilution     
(42°C/24h)
Chloramphenicol, CHL 1-8 1-4 None None
Ciprofloxacin, CIP 0.06-0.25 0.03-0.12 0.12-1 0.06-0.5
Erythromycin, ERY 0.5-2 0.25-2 1-8 1-4
Gentamicin, GEN 0.5-2 0.25-2 0.5-2 0.5-4
Nalidixic acid, NAL 4-16 4-16 None None
Tetracycline, TET 0.25-2 0.25-1 None None
31-37 (30µg)
11-17 (10µg)
28-34 (10µg)
29-36 (10µg)
0.03-0.12
0.06-0.5
29-35 (30µg)
25-32 (30µg)
0.06-0.25
0.5-2
Ranges are according to CLSI (VET01-S2) 
Campylobacter jejuni ATCC 33560
E. coli ATCC 25922
DD (disc content)
16-22 (10µg)
21-27 (30µg)
21-28 (5µg)
MIC ranges and disc diffusion ranges are according to CLSI M100 S23 (range for ciprofloxacin 
extended to include 0.016).
22-28 (30µg)
15-23 (250/300µg)
30-40 (5µg)
0.5-2
19-26 (10µg)
26-32 (10µg)
18-25 (30µg)
1-4
8-32
MIC
2-8
2-8
0.004-0.016
0.25-1
0.015-0.12
0.25-2
0.008-0.06
0.004-0.015
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Test results from the reference strain E. coli ATCC 25922
Lab no. Antimicrobial Operator Value Low limit High limit Mark Method
1 Ampicillin, AMP = 4 2 8 1 MIC
1 Cefotaxime, CTX <= 0.125 0.03 0.125 1 MIC
1 Chloramphenicol, CHL = 4 2 8 1 MIC
1 Ciprofloxacin, CIP <= 0.015 0.004 0.016 1 MIC
1 Colistin, COL <= 1 0.25 2 1 MIC
1 Gentamicin, GEN <= 0.5 0.25 1 1 MIC
1 Nalidixic acid, NAL <= 4 1 4 1 MIC
1 Tetracycline, TET <= 2 0.5 2 1 MIC
1 Trimethoprim, TMP <= 1 0.5 2 1 MIC
2 Ampicillin, AMP = 4 2 8 1 MIC
2 Cefotaxime, CTX <= 0.06 0.03 0.125 1 MIC
2 Ceftazidime, CAZ <= 0.25 0.06 0.5 1 MIC
2 Chloramphenicol, CHL = 4 2 8 1 MIC
2 Ciprofloxacin, CIP = 0.015 0.004 0.016 1 MIC
2 Colistin, COL <= 2 0.25 2 1 MIC
2 Gentamicin, GEN = 0.5 0.25 1 1 MIC
2 Nalidixic acid, NAL <= 4 1 4 1 MIC
2 Sulfisoxazole, FIS = 16 8 32 1 MIC
2 Tetracycline, TET <= 1 0.5 2 1 MIC
2 Trimethoprim, TMP <= 0.5 0.5 2 1 MIC
4 Ampicillin, AMP = 8 2 8 1 MIC
4 Cefotaxime, CTX = 0.06 0.03 0.125 1 MIC
4 Ceftazidime, CAZ = 0.25 0.06 0.5 1 MIC
4 Chloramphenicol, CHL = 8 2 8 1 MIC
4 Ciprofloxacin, CIP = 0.015 0.004 0.016 1 MIC
4 Colistin, COL = 2 0.25 2 1 MIC
4 Gentamicin, GEN = 0.5 0.25 1 1 MIC
4 Nalidixic acid, NAL = 4 1 4 1 MIC
4 Sulfisoxazole, FIS = 32 8 32 1 MIC
4 Tetracycline, TET = 2 0.5 2 1 MIC
4 Trimethoprim, TMP = 0.5 0.5 2 1 MIC
6 Ampicillin, AMP = 2 2 8 1 MIC
6 Cefotaxime, CTX < 0.06 0.03 0.125 1 MIC
6 Ceftazidime, CAZ < 0.25 0.06 0.5 1 MIC
6 Chloramphenicol, CHL = 4 2 8 1 MIC
6 Ciprofloxacin, CIP < 0.008 0.004 0.016 1 MIC
6 Gentamicin, GEN = 0.5 0.25 1 1 MIC
6 Nalidixic acid, NAL < 4 1 4 1 MIC
6 Tetracycline, TET < 1 0.5 2 1 MIC
6 Trimethoprim, TMP < 0.5 0.5 2 1 MIC
9 Ampicillin, AMP = 4 2 8 1 MIC
9 Cefepime, FEP = 0.06 0.015 0.125 1 MIC
9 Cefotaxime, CTX = 0.06 0.03 0.125 1 MIC
9 Cefoxitin, FOX = 4 2 8 1 MIC
9 Ceftazidime, CAZ = 0.25 0.06 0.5 1 MIC
9 Chloramphenicol, CHL = 4 2 8 1 MIC
9 Ciprofloxacin, CIP = 0.008 0.004 0.016 1 MIC
9 Colistin, COL = 0.5 0.25 2 1 MIC
9 Ertapenem, ERTA = 0.008 0.004 0.016 1 MIC
9 Gentamicin, GEN = 0.5 0.25 1 1 MIC
9 Imipenem, IMI = 0.12 0.06 0.25 1 MIC
9 Meropenem, MER = 0.015 0.008 0.06 1 MIC
9 Nalidixic acid, NAL = 4 1 4 1 MIC
9 Sulfisoxazole, FIS = 16 8 32 1 MIC
9 Tetracycline, TET = 1 0.5 2 1 MIC
9 Trimethoprim, TMP = 1 0.5 2 1 MIC
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11 Ampicillin, AMP = 2 2 8 1 MIC
11 Cefotaxime, CTX = 0.06 0.03 0.125 1 MIC
11 Ceftazidime, CAZ <= 0.25 0.06 0.5 1 MIC
11 Chloramphenicol, CHL <= 2 2 8 1 MIC
11 Ciprofloxacin, CIP = 0.016 0.004 0.016 1 MIC
11 Colistin, COL <= 0.5 0.25 2 1 MIC
11 Gentamicin, GEN = 1 0.25 1 1 MIC
11 Nalidixic acid, NAL = 4 1 4 1 MIC
11 Sulfisoxazole, FIS <= 8 8 32 1 MIC
11 Tetracycline, TET <= 1 0.5 2 1 MIC
11 Trimethoprim, TMP = 0.5 0.5 2 1 MIC
12 Ampicillin, AMP = 4 2 8 1 MIC
12 Cefotaxime, CTX = 0.12 0.03 0.125 1 MIC
12 Cefoxitin, FOX = 4 2 8 1 MIC
12 Ceftazidime, CAZ = 0.5 0.06 0.5 1 MIC
12 Chloramphenicol, CHL = 4 2 8 1 MIC
12 Ciprofloxacin, CIP = 0.03 0.004 0.016 0 MIC
12 Colistin, COL = 1 0.25 2 1 MIC
12 Gentamicin, GEN = 1 0.25 1 1 MIC
12 Nalidixic acid, NAL = 2 1 4 1 MIC
12 Tetracycline, TET = 2 0.5 2 1 MIC
12 Trimethoprim, TMP = 1 0.5 2 1 MIC
13 Ampicillin, AMP = 8 2 8 1 MIC
13 Cefotaxime, CTX <= 0.06 0.03 0.125 1 MIC
13 Ceftazidime, CAZ <= 0.25 0.06 0.5 1 MIC
13 Chloramphenicol, CHL = 8 2 8 1 MIC
13 Ciprofloxacin, CIP = 0.015 0.004 0.016 1 MIC
13 Gentamicin, GEN = 0.5 0.25 1 1 MIC
13 Nalidixic acid, NAL <= 4 1 4 1 MIC
13 Sulfisoxazole, FIS = 16 8 32 1 MIC
13 Tetracycline, TET = 2 0.5 2 1 MIC
13 Trimethoprim, TMP <= 0.5 0.5 2 1 MIC
15 Cefepime, FEP = 36 31 37 1 DD
15 Cefotaxime, CTX = 35 29 35 1 DD
15 Cefoxitin, FOX = 29 23 29 1 DD
15 Ceftazidime, CAZ = 32 25 32 1 DD
15 Chloramphenicol, CHL = 26 21 27 1 DD
15 Colistin, COL = 19 11 17 0 DD
15 Ertapenem, ERTA = 36 29 36 1 DD
15 Gentamicin, GEN = 26 19 26 1 DD
15 Nalidixic acid, NAL = 25 22 28 1 DD
15 Sulfisoxazole, FIS = 18 15 23 1 DD
15 Tetracycline, TET = 25 18 25 1 DD
15 Trimethoprim, TMP = 28 21 28 1 DD
16 Ampicillin, AMP = 8 2 8 1 MIC
16 Cefotaxime, CTX = 0.12 0.03 0.125 1 MIC
16 Ceftazidime, CAZ = 0.25 0.06 0.5 1 MIC
16 Chloramphenicol, CHL <= 4 2 8 1 MIC
16 Ciprofloxacin, CIP = 0.015 0.004 0.016 1 MIC
16 Colistin, COL = 1 0.25 2 1 MIC
16 Gentamicin, GEN <= 0.5 0.25 1 1 MIC
16 Meropenem, MER <= 0.12 0.008 0.06 1 MIC
16 Nalidixic acid, NAL <= 2 1 4 1 MIC
16 Tetracycline, TET <= 1 0.5 2 1 MIC
16 Trimethoprim, TMP = 0.5 0.5 2 1 MIC
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17 Ampicillin, AMP = 4 2 8 1 MIC
17 Cefotaxime, CTX = 0.12 0.03 0.125 1 MIC
17 Ceftazidime, CAZ <= 0.25 0.06 0.5 1 MIC
17 Chloramphenicol, CHL = 8 2 8 1 MIC
17 Ciprofloxacin, CIP = 0.015 0.004 0.016 1 MIC
17 Colistin, COL <= 2 0.25 2 1 MIC
17 Gentamicin, GEN = 0.5 0.25 1 1 MIC
17 Nalidixic acid, NAL <= 4 1 4 1 MIC
17 Sulfisoxazole, FIS = 32 8 32 1 MIC
17 Tetracycline, TET <= 1 0.5 2 1 MIC
17 Trimethoprim, TMP = 1 0.5 2 1 MIC
18 Ampicillin, AMP = 4 2 8 1 MIC
18 Cefotaxime, CTX = 0.12 0.03 0.125 1 MIC
18 Ceftazidime, CAZ <= 0.25 0.06 0.5 1 MIC
18 Chloramphenicol, CHL = 4 2 8 1 MIC
18 Ciprofloxacin, CIP = 0.008 0.004 0.016 1 MIC
18 Colistin, COL <= 2 0.25 2 1 MIC
18 Gentamicin, GEN = 0.5 0.25 1 1 MIC
18 Nalidixic acid, NAL <= 4 1 4 1 MIC
18 Sulfisoxazole, FIS = 32 8 32 1 MIC
18 Tetracycline, TET = 2 0.5 2 1 MIC
18 Trimethoprim, TMP <= 0.5 0.5 2 1 MIC
19 Ampicillin, AMP = 8 2 8 1 MIC
19 Cefotaxime, CTX <= 0.06 0.03 0.125 1 MIC
19 Ceftazidime, CAZ = 0.5 0.06 0.5 1 MIC
19 Chloramphenicol, CHL = 4 2 8 1 MIC
19 Ciprofloxacin, CIP = 0.015 0.004 0.016 1 MIC
19 Colistin, COL <= 2 0.25 2 1 MIC
19 Gentamicin, GEN = 0.5 0.25 1 1 MIC
19 Nalidixic acid, NAL <= 4 1 4 1 MIC
19 Sulfisoxazole, FIS = 64 8 32 0 MIC
19 Tetracycline, TET = 2 0.5 2 1 MIC
19 Trimethoprim, TMP = 1 0.5 2 1 MIC
20 Ampicillin, AMP = 4 2 8 1 MIC
20 Cefepime, FEP <= 1 0.015 0.125 1 MIC
20 Cefotaxime, CTX <= 0.06 0.03 0.125 1 MIC
20 Cefoxitin, FOX <= 4 2 8 1 MIC
20 Ceftazidime, CAZ <= 0.25 0.06 0.5 1 MIC
20 Chloramphenicol, CHL = 4 2 8 1 MIC
20 Ciprofloxacin, CIP = 0.015 0.004 0.016 1 MIC
20 Colistin, COL <= 2 0.25 2 1 MIC
20 Ertapenem, ERTA = 0.5 0.004 0.016 0 MIC
20 Gentamicin, GEN = 0.5 0.25 1 1 MIC
20 Imipenem, IMI = 30 26 32 1 DD
20 Meropenem, MER = 32 28 34 1 DD
20 Nalidixic acid, NAL <= 4 1 4 1 MIC
20 Sulfisoxazole, FIS = 32 8 32 1 MIC
20 Tetracycline, TET <= 1 0.5 2 1 MIC
20 Trimethoprim, TMP <= 0.5 0.5 2 1 MIC
21 Ampicillin, AMP = 2 2 8 1 MIC
21 Cefotaxime, CTX = 0.06 0.03 0.125 1 MIC
21 Ceftazidime, CAZ = 0.25 0.06 0.5 1 MIC
21 Chloramphenicol, CHL = 4 2 8 1 MIC
21 Ciprofloxacin, CIP = 0.008 0.004 0.016 1 MIC
21 Colistin, COL = 2 0.25 2 1 MIC
21 Gentamicin, GEN = 0.5 0.25 1 1 MIC
21 Nalidixic acid, NAL = 4 1 4 1 MIC
21 Sulfisoxazole, FIS = 32 8 32 1 MIC
21 Tetracycline, TET = 1 0.5 2 1 MIC
21 Trimethoprim, TMP = 0.5 0.5 2 1 MIC
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22 Ampicillin, AMP = 4 2 8 1 MIC
22 Cefotaxime, CTX < 0.06 0.03 0.125 1 MIC
22 Ceftazidime, CAZ < 0.25 0.06 0.5 1 MIC
22 Chloramphenicol, CHL = 4 2 8 1 MIC
22 Ciprofloxacin, CIP = 0.015 0.004 0.016 1 MIC
22 Colistin, COL = 2 0.25 2 1 MIC
22 Gentamicin, GEN = 0.5 0.25 1 1 MIC
22 Nalidixic acid, NAL < 4 1 4 1 MIC
22 Sulfisoxazole, FIS = 16 8 32 1 MIC
22 Tetracycline, TET < 1 0.5 2 1 MIC
22 Trimethoprim, TMP = 0.5 0.5 2 1 MIC
23 Ampicillin, AMP = 2 2 8 1 MIC
23 Cefotaxime, CTX = 0.06 0.03 0.125 1 MIC
23 Ceftazidime, CAZ = 0.25 0.06 0.5 1 MIC
23 Chloramphenicol, CHL = 4 2 8 1 MIC
23 Ciprofloxacin, CIP = 0.008 0.004 0.016 1 MIC
23 Colistin, COL < 2 0.25 2 1 MIC
23 Gentamicin, GEN = 0.5 0.25 1 1 MIC
23 Nalidixic acid, NAL = 4 1 4 1 MIC
23 Sulfisoxazole, FIS = 32 8 32 1 MIC
23 Tetracycline, TET = 1 0.5 2 1 MIC
23 Trimethoprim, TMP = 1 0.5 2 1 MIC
25 Ampicillin, AMP = 4 2 8 1 MIC
25 Cefotaxime, CTX = 0.12 0.03 0.125 1 MIC
25 Ceftazidime, CAZ <= 0.25 0.06 0.5 1 MIC
25 Chloramphenicol, CHL = 8 2 8 1 MIC
25 Ciprofloxacin, CIP = 0.015 0.004 0.016 1 MIC
25 Colistin, COL <= 2 0.25 2 1 MIC
25 Gentamicin, GEN = 0.5 0.25 1 1 MIC
25 Nalidixic acid, NAL <= 4 1 4 1 MIC
25 Sulfisoxazole, FIS <= 8 8 32 1 MIC
25 Tetracycline, TET <= 1 0.5 2 1 MIC
25 Trimethoprim, TMP <= 0.5 0.5 2 1 MIC
26 Ampicillin, AMP = 2 2 8 1 MIC
26 Cefotaxime, CTX = 0.12 0.03 0.125 1 MIC
26 Ceftazidime, CAZ <= 0.25 0.06 0.5 1 MIC
26 Chloramphenicol, CHL = 4 2 8 1 MIC
26 Ciprofloxacin, CIP <= 0.008 0.004 0.016 1 MIC
26 Colistin, COL <= 2 0.25 2 1 MIC
26 Gentamicin, GEN = 0.5 0.25 1 1 MIC
26 Nalidixic acid, NAL <= 4 1 4 1 MIC
26 Tetracycline, TET <= 1 0.5 2 1 MIC
26 Trimethoprim, TMP <= 0.5 0.5 2 1 MIC
29 Ampicillin, AMP = 4 2 8 1 MIC
29 Cefotaxime, CTX = 0.06 0.03 0.125 1 MIC
29 Ceftazidime, CAZ = 0.5 0.06 0.5 1 MIC
29 Chloramphenicol, CHL = 8 2 8 1 MIC
29 Ciprofloxacin, CIP = 0.016 0.004 0.016 1 MIC
29 Gentamicin, GEN = 0.5 0.25 1 1 MIC
29 Nalidixic acid, NAL = 0.5 1 4 0 MIC
29 Tetracycline, TET = 0.5 0.5 2 1 MIC
29 Trimethoprim, TMP = 1 0.5 2 1 MIC
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30 Ampicillin, AMP = 8 2 8 1 MIC
30 Cefepime, FEP <= 1 0.015 0.125 1 MIC
30 Cefotaxime, CTX = 0.12 0.03 0.125 1 MIC
30 Cefoxitin, FOX <= 4 2 8 1 MIC
30 Ceftazidime, CAZ <= 0.25 0.06 0.5 1 MIC
30 Chloramphenicol, CHL = 4 2 8 1 MIC
30 Ciprofloxacin, CIP = 0.015 0.004 0.016 1 MIC
30 Colistin, COL <= 2 0.25 2 1 MIC
30 Gentamicin, GEN = 1 0.25 1 1 MIC
30 Imipenem, IMI <= 0.5 0.06 0.25 1 MIC
30 Meropenem, MER <= 1 0.008 0.06 1 MIC
30 Nalidixic acid, NAL <= 4 1 4 1 MIC
30 Sulfisoxazole, FIS = 32 8 32 1 MIC
30 Tetracycline, TET <= 1 0.5 2 1 MIC
30 Trimethoprim, TMP <= 0.5 0.5 2 1 MIC
32 Ampicillin, AMP = 4 2 8 1 MIC
32 Cefotaxime, CTX <= 0.06 0.03 0.125 1 MIC
32 Ceftazidime, CAZ <= 0.25 0.06 0.5 1 MIC
32 Chloramphenicol, CHL = 4 2 8 1 MIC
32 Ciprofloxacin, CIP <= 0.008 0.004 0.016 1 MIC
32 Colistin, COL <= 2 0.25 2 1 MIC
32 Gentamicin, GEN = 0.5 0.25 1 1 MIC
32 Meropenem, MER = 0.008 0.008 0.06 1 MIC
32 Nalidixic acid, NAL <= 4 1 4 1 MIC
32 Sulfisoxazole, FIS = 16 8 32 1 MIC
32 Tetracycline, TET <= 1 0.5 2 1 MIC
32 Trimethoprim, TMP <= 0.5 0.5 2 1 MIC
33 Ampicillin, AMP = 4 2 8 1 MIC
33 Cefotaxime, CTX = 0.06 0.03 0.125 1 MIC
33 Ceftazidime, CAZ = 0.5 0.06 0.5 1 MIC
33 Chloramphenicol, CHL = 4 2 8 1 MIC
33 Ciprofloxacin, CIP = 0.03 0.004 0.016 0 MIC
33 Colistin, COL = 1 0.25 2 1 MIC
33 Gentamicin, GEN = 0.5 0.25 1 1 MIC
33 Nalidixic acid, NAL = 4 1 4 1 MIC
33 Tetracycline, TET <= 1 0.5 2 1 MIC
33 Trimethoprim, TMP = 0.5 0.5 2 1 MIC
34 Ampicillin, AMP = 4 2 8 1 MIC
34 Cefotaxime, CTX <= 0.06 0.03 0.125 1 MIC
34 Ceftazidime, CAZ = 0.5 0.06 0.5 1 MIC
34 Chloramphenicol, CHL = 4 2 8 1 MIC
34 Ciprofloxacin, CIP = 0.015 0.004 0.016 1 MIC
34 Colistin, COL <= 2 0.25 2 1 MIC
34 Gentamicin, GEN = 0.5 0.25 1 1 MIC
34 Nalidixic acid, NAL <= 4 1 4 1 MIC
34 Sulfisoxazole, FIS = 128 8 32 0 MIC
34 Tetracycline, TET <= 1 0.5 2 1 MIC
34 Trimethoprim, TMP <= 0.5 0.5 2 1 MIC
36 Ampicillin, AMP = 8 2 8 1 MIC
36 Cefotaxime, CTX = 0.12 0.03 0.125 1 MIC
36 Ceftazidime, CAZ <= 0.25 0.06 0.5 1 MIC
36 Chloramphenicol, CHL = 4 2 8 1 MIC
36 Ciprofloxacin, CIP = 0.03 0.004 0.016 0 MIC
36 Colistin, COL <= 0.5 0.25 2 1 MIC
36 Gentamicin, GEN = 0.5 0.25 1 1 MIC
36 Nalidixic acid, NAL = 2 1 4 1 MIC
36 Sulfisoxazole, FIS = 16 8 32 1 MIC
36 Tetracycline, TET <= 1 0.5 2 1 MIC
36 Trimethoprim, TMP = 0.5 0.5 2 1 MIC
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37 Ampicillin, AMP = 4 2 8 1 AGA
37 Cefotaxime, CTX <= 0.06 0.03 0.125 1 AGA
37 Ceftazidime, CAZ = 0.5 0.06 0.5 1 AGA
37 Chloramphenicol, CHL = 4 2 8 1 AGA
37 Ciprofloxacin, CIP <= 0.008 0.004 0.016 1 AGA
37 Gentamicin, GEN = 0.5 0.25 1 1 AGA
37 Nalidixic acid, NAL <= 2 1 4 1 AGA
37 Tetracycline, TET = 1 0.5 2 1 AGA
37 Trimethoprim, TMP = 0.5 0.5 2 1 AGA
39 Ampicillin, AMP = 4 2 8 1 MIC
39 Cefotaxime, CTX = 0.12 0.03 0.125 1 MIC
39 Ceftazidime, CAZ = 0.5 0.06 0.5 1 MIC
39 Chloramphenicol, CHL = 4 2 8 1 MIC
39 Ciprofloxacin, CIP = 0.016 0.004 0.016 1 MIC
39 Colistin, COL <= 0.5 0.25 2 1 MIC
39 Gentamicin, GEN = 0.5 0.25 1 1 MIC
39 Nalidixic acid, NAL = 2 1 4 1 MIC
39 Tetracycline, TET <= 1 0.5 2 1 MIC
39 Trimethoprim, TMP = 0.5 0.5 2 1 MIC
40 Ampicillin, AMP = 20 16 22 1 DD
40 Cefepime, FEP = 32 31 37 1 DD
40 Cefotaxime, CTX = 34 29 35 1 DD
40 Cefoxitin, FOX = 28 23 29 1 DD
40 Ceftazidime, CAZ = 30 25 32 1 DD
40 Chloramphenicol, CHL = 24 21 27 1 DD
40 Ciprofloxacin, CIP = 33 30 40 1 DD
40 Gentamicin, GEN = 21 19 26 1 DD
40 Imipenem, IMI = 31 26 32 1 DD
40 Meropenem, MER = 30 28 34 1 DD
40 Nalidixic acid, NAL = 24 22 28 1 DD
40 Sulfisoxazole, FIS = 23 15 23 1 DD
40 Tetracycline, TET = 23 18 25 1 DD
40 Trimethoprim, TMP = 28 21 28 1 DD
41 Ampicillin, AMP = 4 2 8 1 MIC
41 Cefotaxime, CTX = 0.06 0.03 0.125 1 MIC
41 Ceftazidime, CAZ = 0.25 0.06 0.5 1 MIC
41 Chloramphenicol, CHL = 8 2 8 1 MIC
41 Ciprofloxacin, CIP = 0.015 0.004 0.016 1 MIC
41 Colistin, COL = 2 0.25 2 1 MIC
41 Gentamicin, GEN = 0.5 0.25 1 1 MIC
41 Nalidixic acid, NAL = 4 1 4 1 MIC
41 Tetracycline, TET = 1 0.5 2 1 MIC
41 Trimethoprim, TMP = 1 0.5 2 1 MIC
42 Ampicillin, AMP = 4 2 8 1 MIC
42 Cefepime, FEP <= 1 0.015 0.125 1 MIC
42 Cefotaxime, CTX = 0.12 0.03 0.125 1 MIC
42 Cefoxitin, FOX <= 4 2 8 1 MIC
42 Ceftazidime, CAZ <= 0.25 0.06 0.5 1 MIC
42 Chloramphenicol, CHL = 8 2 8 1 MIC
42 Ciprofloxacin, CIP = 0.015 0.004 0.016 1 MIC
42 Colistin, COL <= 2 0.25 2 1 MIC
42 Gentamicin, GEN = 0.5 0.25 1 1 MIC
42 Imipenem, IMI = 0.25 0.06 0.25 1 MIC
42 Meropenem, MER <= 1 0.008 0.06 1 MIC
42 Nalidixic acid, NAL <= 4 1 4 1 MIC
42 Sulfisoxazole, FIS = 32 8 32 1 MIC
42 Tetracycline, TET = 2 0.5 2 1 MIC
42 Trimethoprim, TMP = 1 0.5 2 1 MIC
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44 Ampicillin, AMP <= 8 2 8 1 AGA
44 Cefotaxime, CTX <= 0.5 0.03 0.125 1 AGA
44 Cefoxitin, FOX <= 8 2 8 1 AGA
44 Ceftazidime, CAZ <= 1 0.06 0.5 1 AGA
44 Chloramphenicol, CHL <= 8 2 8 1 AGA
44 Ciprofloxacin, CIP <= 0.064 0.004 0.016 1 AGA
44 Colistin, COL <= 2 0.25 2 1 AGA
44 Ertapenem, ERTA <= 0.064 0.004 0.016 1 AGA
44 Gentamicin, GEN <= 2 0.25 1 1 AGA
44 Imipenem, IMI = 0.19 0.06 0.25 1 AGA
44 Meropenem, MER = 0.008 0.008 0.06 1 AGA
44 Nalidixic acid, NAL <= 16 1 4 1 AGA
44 Sulfisoxazole, FIS <= 256 8 32 1 AGA
44 Tetracycline, TET <= 8 0.5 2 1 AGA
44 Trimethoprim, TMP <= 2 0.5 2 1 AGA
45 Ampicillin, AMP = 14.6 16 22 0 DD
45 Cefotaxime, CTX = 32.0 29 35 1 DD
45 Cefoxitin, FOX = 23.6 23 29 1 DD
45 Ceftazidime, CAZ = 27.8 25 32 1 DD
45 Chloramphenicol, CHL = 26.3 21 27 1 DD
45 Ciprofloxacin, CIP = 35.1 30 40 1 DD
45 Colistin, COL = 13.8 11 17 1 DD
45 Gentamicin, GEN = 18.6 19 26 0 DD
45 Meropenem, MER = 32.4 28 34 1 DD
45 Nalidixic acid, NAL = 25.5 22 28 1 DD
45 Sulfisoxazole, FIS = 19.5 15 23 1 DD
45 Tetracycline, TET = 22.9 18 25 1 DD
45 Trimethoprim, TMP = 25.0 21 28 1 DD
56 Ampicillin, AMP = 4 2 8 1 MIC
56 Cefepime, FEP = 32 31 37 1 DD
56 Cefotaxime, CTX <= 0.06 0.03 0.125 1 MIC
56 Cefoxitin, FOX = 26 23 29 1 DD
56 Ceftazidime, CAZ <= 0.25 0.06 0.5 1 MIC
56 Chloramphenicol, CHL = 4 2 8 1 MIC
56 Ciprofloxacin, CIP = 0.015 0.004 0.016 1 MIC
56 Colistin, COL < 2 0.25 2 1 MIC
56 Gentamicin, GEN = 0.5 0.25 1 1 MIC
56 Meropenem, MER = 30 28 34 1 DD
56 Nalidixic acid, NAL <= 4 1 4 1 MIC
56 Sulfisoxazole, FIS = 32 8 32 1 MIC
56 Tetracycline, TET <= 1 0.5 2 1 MIC
56 Trimethoprim, TMP = 1 0.5 2 1 MIC
58 Ampicillin, AMP = 4 2 8 1 MIC
58 Cefepime, FEP = 0.094 0.015 0.125 1 MIC
58 Cefotaxime, CTX <= 0.06 0.03 0.125 1 MIC
58 Cefoxitin, FOX <= 4 2 8 1 MIC
58 Ceftazidime, CAZ <= 0.25 0.06 0.5 1 MIC
58 Chloramphenicol, CHL = 8 2 8 1 MIC
58 Ciprofloxacin, CIP <= 0.008 0.004 0.016 1 MIC
58 Colistin, COL <= 2 0.25 2 1 MIC
58 Ertapenem, ERTA = 0.06 0.004 0.016 0 MIC
58 Gentamicin, GEN = 0.5 0.25 1 1 MIC
58 Imipenem, IMI = 0.5 0.06 0.25 0 MIC
58 Meropenem, MER = 0.016 0.008 0.06 1 MIC
58 Nalidixic acid, NAL <= 4 1 4 1 MIC
58 Sulfisoxazole, FIS = 32 8 32 1 MIC
58 Tetracycline, TET <= 1 0.5 2 1 MIC
58 Trimethoprim, TMP <= 0.5 0.5 2 1 MIC
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Test results from the reference strain C. jejuni ATCC 33560
Lab no. Antimicrobial Operator Value Low limit High limit Mark Method 36-37ºC/48h 42ºC/24h
1 Ciprofloxacin, CIP = 0.25 0,06 0,25 1 MIC X
1 Erythromycin, ERY = 2 0,5 2 1 MIC X
1 Gentamicin, GEN = 0.25 0,5 2 0 MIC X
1 Nalidixic acid, NAL = 8 4 16 1 MIC X
1 Tetracycline, TET = 2 0,25 2 1 MIC X
2 Ciprofloxacin, CIP = 0.25 0,06 0,25 1 MIC X
2 Erythromycin, ERY = 1 0,5 2 1 MIC X
2 Gentamicin, GEN = 0.25 0,5 2 0 MIC X
2 Nalidixic acid, NAL = 8 4 16 1 MIC X
2 Tetracycline, TET = 1 0,25 2 1 MIC X
4 Ciprofloxacin, CIP = 0.12 0,06 0,25 1 MIC X
4 Erythromycin, ERY = 2 0,5 2 1 MIC X
4 Gentamicin, GEN = 1 0,5 2 1 MIC X
4 Nalidixic acid, NAL = 4 4 16 1 MIC X
4 Tetracycline, TET = 2 0,25 2 1 MIC X
6 Ciprofloxacin, CIP = 0.12 0,03 0,125 1 MIC X
6 Erythromycin, ERY <= 0.5 0,25 2 1 MIC X
6 Gentamicin, GEN = 1 0,25 2 1 MIC X
6 Nalidixic acid, NAL = 8 4 16 1 MIC X
6 Tetracycline, TET = 1 0,25 1 1 MIC X
9 Ciprofloxacin, CIP = 0.12 0,06 0,25 1 MIC X
9 Erythromycin, ERY = 1 0,5 2 1 MIC X
9 Gentamicin, GEN = 1 0,5 2 1 MIC X
9 Nalidixic acid, NAL = 8 4 16 1 MIC X
9 Tetracycline, TET = 0.5 0,25 2 1 MIC X
11 Ciprofloxacin, CIP = 0.25 0,03 0,125 0 MIC X
11 Erythromycin, ERY <= 0.5 0,25 2 1 MIC X
11 Gentamicin, GEN = 1 0,25 2 1 MIC X
11 Nalidixic acid, NAL = 8 4 16 1 MIC X
11 Tetracycline, TET = 1 0,25 1 1 MIC X
12 Ciprofloxacin, CIP = 0.5 0,06 0,25 0 MIC X
12 Erythromycin, ERY = 2 0,5 2 1 MIC X
12 Gentamicin, GEN = 1 0,5 2 1 MIC X
12 Nalidixic acid, NAL = 16 4 16 1 MIC X
12 Tetracycline, TET = 1 0,25 2 1 MIC X
14 Ciprofloxacin, CIP = 0.125 0,03 0,125 1 MIC X
14 Erythromycin, ERY <= 0.5 0,25 2 1 MIC X
14 Gentamicin, GEN = 1 0,25 2 1 MIC X
14 Nalidixic acid, NAL = 4 4 16 1 MIC X
14 Tetracycline, TET = 1 0,25 1 1 MIC X
17 Ciprofloxacin, CIP = 0.25 0,06 0,25 1 MIC X
17 Erythromycin, ERY = 2 0,5 2 1 MIC X
17 Gentamicin, GEN = 1 0,5 2 1 MIC X
17 Nalidixic acid, NAL = 8 4 16 1 MIC X
17 Tetracycline, TET = 0.5 0,25 2 1 MIC X
19 Ciprofloxacin, CIP = 0.12 0,03 0,125 1 MIC X
19 Erythromycin, ERY <= 0.5 0,25 2 1 MIC X
19 Gentamicin, GEN = 1 0,25 2 1 MIC X
19 Nalidixic acid, NAL = 4 4 16 1 MIC X
19 Tetracycline, TET = 1 0,25 1 1 MIC X
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20 Ciprofloxacin, CIP = 0.25 0,06 0,25 1 MIC X
20 Erythromycin, ERY = 1 0,5 2 1 MIC X
20 Gentamicin, GEN = 1 0,5 2 1 MIC X
20 Nalidixic acid, NAL = 8 4 16 1 MIC X
20 Tetracycline, TET = 1 0,25 2 1 MIC X
21 Ciprofloxacin, CIP = 0.25 0,03 0,125 0 MIC X
21 Erythromycin, ERY = 0.5 0,25 2 1 MIC X
21 Gentamicin, GEN = 0.12 0,25 2 0 MIC X
21 Nalidixic acid, NAL = 2 4 16 0 MIC X
21 Tetracycline, TET = 0.25 0,25 1 1 MIC X
22 Ciprofloxacin, CIP = 0.12 0,03 0,125 1 MIC X
22 Erythromycin, ERY = 1 0,25 2 1 MIC X
22 Gentamicin, GEN = 0.5 0,25 2 1 MIC X
22 Nalidixic acid, NAL = 8 4 16 1 MIC X
22 Tetracycline, TET = 1 0,25 1 1 MIC X
23 Ciprofloxacin, CIP = 0.12 0,03 0,125 1 MIC X
23 Erythromycin, ERY < 0.5 0,25 2 1 MIC X
23 Gentamicin, GEN = 1 0,25 2 1 MIC X
23 Nalidixic acid, NAL = 8 4 16 1 MIC X
23 Tetracycline, TET = 1 0,25 1 1 MIC X
25 Ciprofloxacin, CIP = 0.25 0,06 0,25 1 MIC X
25 Erythromycin, ERY = 2 0,5 2 1 MIC X
25 Gentamicin, GEN <= 0.25 0,5 2 0 MIC X
25 Nalidixic acid, NAL = 8 4 16 1 MIC X
25 Tetracycline, TET = 2 0,25 2 1 MIC X
26 Ciprofloxacin, CIP = 0.12 0,06 0,25 1 MIC X
26 Erythromycin, ERY = 1 0,5 2 1 MIC X
26 Gentamicin, GEN = 1 0,5 2 1 MIC X
26 Nalidixic acid, NAL = 8 4 16 1 MIC X
26 Tetracycline, TET = 2 0,25 2 1 MIC X
29 Ciprofloxacin, CIP = 0.06 0,06 0,25 1 MIC X
29 Erythromycin, ERY = 1 0,5 2 1 MIC X
29 Gentamicin, GEN = 2 0,5 2 1 MIC X
29 Nalidixic acid, NAL = 4 4 16 1 MIC X
29 Tetracycline, TET = 0.25 0,25 2 1 MIC X
30 Ciprofloxacin, CIP = 0.25 0,06 0,25 1 MIC X
30 Erythromycin, ERY = 1 0,5 2 1 MIC X
30 Gentamicin, GEN = 0.5 0,5 2 1 MIC X
30 Nalidixic acid, NAL = 8 4 16 1 MIC X
30 Tetracycline, TET = 1 0,25 2 1 MIC X
32 Ciprofloxacin, CIP = 0.125 0,06 0,25 1 MIC X
32 Erythromycin, ERY = 1 0,5 2 1 MIC X
32 Gentamicin, GEN = 0.5 0,5 2 1 MIC X
32 Nalidixic acid, NAL = 8 4 16 1 MIC X
32 Tetracycline, TET = 1 0,25 2 1 MIC X
33 Ciprofloxacin, CIP = 0.25 0,06 0,25 1 MIC X
33 Erythromycin, ERY = 1 0,5 2 1 MIC X
33 Gentamicin, GEN = 1 0,5 2 1 MIC X
33 Nalidixic acid, NAL = 8 4 16 1 MIC X
33 Tetracycline, TET = 0.5 0,25 2 1 MIC X
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34 Ciprofloxacin, CIP = 0.25 0,06 0,25 1 MIC X
34 Erythromycin, ERY = 2 0,5 2 1 MIC X
34 Gentamicin, GEN = 0.5 0,5 2 1 MIC X
34 Nalidixic acid, NAL = 8 4 16 1 MIC X
34 Tetracycline, TET = 2 0,25 2 1 MIC X
36 Ciprofloxacin, CIP = 0.25 0,06 0,25 1 MIC X
36 Erythromycin, ERY <= 0.5 0,5 2 1 MIC X
36 Gentamicin, GEN = 0.5 0,5 2 1 MIC X
36 Nalidixic acid, NAL = 8 4 16 1 MIC X
36 Tetracycline, TET = 0.5 0,25 2 1 MIC X
37 Ciprofloxacin, CIP = 0.25 0,12 1 1 AGA X
37 Erythromycin, ERY = 1 1 8 1 AGA X
37 Gentamicin, GEN = 1 0,5 2 1 AGA X
37 Nalidixic acid, NAL = 8 NA NA AGA X
37 Tetracycline, TET = 1 NA NA AGA X
40 Ciprofloxacin, CIP = 0.12 0,03 0,125 1 MIC X
40 Erythromycin, ERY = 0.5 0,25 2 1 MIC X
40 Gentamicin, GEN = 0.25 0,25 2 1 MIC X
40 Nalidixic acid, NAL = 4 4 16 1 MIC X
40 Tetracycline, TET = 1 0,25 1 1 MIC X
41 Ciprofloxacin, CIP = 0.06 0,03 0,125 1 MIC X
41 Erythromycin, ERY = 0.5 0,25 2 1 MIC X
41 Gentamicin, GEN = 1 0,25 2 1 MIC X
41 Nalidixic acid, NAL = 4 4 16 1 MIC X
41 Tetracycline, TET = 0.5 0,25 1 1 MIC X
42 Ciprofloxacin, CIP = 0.12 0,06 0,25 1 MIC X
42 Erythromycin, ERY = 1 0,5 2 1 MIC X
42 Gentamicin, GEN = 0.25 0,5 2 0 MIC X
42 Nalidixic acid, NAL = 8 4 16 1 MIC X
42 Tetracycline, TET = 1 0,25 2 1 MIC X
44 Ciprofloxacin, CIP < 1 0,12 1 1 AGA X
44 Erythromycin, ERY < 4 1 8 1 AGA X
44 Gentamicin, GEN < 1 0,5 2 1 AGA X
44 Nalidixic acid, NAL < 16 NA NA AGA X
44 Tetracycline, TET < 2 NA NA AGA X
45 Ciprofloxacin, CIP = 0.12 0,06 0,25 1 MIC X
45 Erythromycin, ERY = 1 0,5 2 1 MIC X
45 Gentamicin, GEN = 1 0,5 2 1 MIC X
45 Nalidixic acid, NAL = 8 4 16 1 MIC X
45 Tetracycline, TET = 1 0,25 2 1 MIC X
56 Ciprofloxacin, CIP = 0.12 0,03 0,125 1 MIC X
56 Erythromycin, ERY <= 0.5 0,25 2 1 MIC X
56 Gentamicin, GEN = 1 0,25 2 1 MIC X
56 Nalidixic acid, NAL = 8 4 16 1 MIC X
56 Tetracycline, TET = 1 0,25 1 1 MIC X
58 Ciprofloxacin, CIP = 0.12 0,03 0,125 1 MIC X
58 Erythromycin, ERY = 1 0,25 2 1 MIC X
58 Gentamicin, GEN = 1 0,25 2 1 MIC X
58 Nalidixic acid, NAL = 8 4 16 1 MIC X
58 Tetracycline, TET = 1 0,25 1 1 MIC X
MIC: microbroth dilution
AGA: agar dilution
NA: Not available
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Salmonella - expected and obtained interpretation
Antimicrobial Strain Expected % R % S No. correct No. incorrect
EURL S-8.1 S 0 100 34 0
EURL S-8.2 S 0 100 34 0
EURL S-8.3 R 100 0 34 0
EURL S-8.4 R 100 0 34 0
EURL S-8.5 R 100 0 34 0
EURL S-8.6 R 100 0 34 0
EURL S-8.7 R 100 0 34 0
EURL S-8.8 R 97 3 33 1
EURL S-8.1 S 0 100 34 0
EURL S-8.2 S 0 100 34 0
EURL S-8.3 S 0 100 34 0
EURL S-8.4 R 100 0 34 0
EURL S-8.5 R 100 0 34 0
EURL S-8.6 R 100 0 34 0
EURL S-8.7 R 100 0 34 0
EURL S-8.8 S 3 97 33 1
EURL S-8.1 S 0 100 33 0
EURL S-8.2 S 0 100 33 0
EURL S-8.3 S 0 100 33 0
EURL S-8.4 R 100 0 34 0
EURL S-8.5 S 6 94 31 2
EURL S-8.6 R 100 0 34 0
EURL S-8.7 R 100 0 34 0
EURL S-8.8 S 3 97 32 1
EURL S-8.1 S 0 100 34 0
EURL S-8.2 S 0 100 34 0
EURL S-8.3 S 3 97 33 1
EURL S-8.4 S 0 100 34 0
EURL S-8.5 S 0 100 34 0
EURL S-8.6 R 100 0 34 0
EURL S-8.7 S 0 100 34 0
EURL S-8.8 R 97 3 33 1
EURL S-8.1 R 94 6 32 2
EURL S-8.2 S 0 100 34 0
EURL S-8.3 R 100 0 34 0
EURL S-8.4 R 100 0 34 0
EURL S-8.5 R 97 3 33 1
EURL S-8.6 R 97 3 33 1
EURL S-8.7 S 3 97 33 1
EURL S-8.8 S 0 100 34 0
EURL S-8.1 S 0 100 30 0
EURL S-8.2 S 7 93 28 2
EURL S-8.3 S 3 97 29 1
EURL S-8.4 S 0 100 30 0
EURL S-8.5 S 0 100 30 0
EURL S-8.6 S 0 100 30 0
EURL S-8.7 S 0 100 30 0
EURL S-8.8 S 3 97 29 1
Ampicillin, AMP
Colistin, COL
Ciprofloxacin, CIP
Chloramphenicol, CHL
Ceftazidime, CAZ
Cefotaxime, CTX
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Antimicrobial Strain Expected % R % S No. correct No. incorrect
EURL S-8.1 S 0 100 34 0
EURL S-8.2 S 0 100 34 0
EURL S-8.3 R 100 0 34 0
EURL S-8.4 R 100 0 34 0
EURL S-8.5 S 3 97 33 1
EURL S-8.6 R 100 0 34 0
EURL S-8.7 S 0 100 34 0
EURL S-8.8 S 0 100 34 0
EURL S-8.1 S 0 100 14 0
EURL S-8.2 S 0 100 13 0
EURL S-8.3 S 0 100 15 0
EURL S-8.4* R 38 62 5 8
EURL S-8.5 S 0 100 14 0
EURL S-8.6 S 0 100 14 0
EURL S-8.7 S 0 100 15 0
EURL S-8.8 S 0 100 14 0
EURL S-8.1 S 0 100 34 0
EURL S-8.2 S 0 100 34 0
EURL S-8.3 R 100 0 34 0
EURL S-8.4 R 97 3 33 1
EURL S-8.5 R 97 3 33 1
EURL S-8.6 R 100 0 34 0
EURL S-8.7 S 0 100 34 0
EURL S-8.8 S 0 100 34 0
EURL S-8.1 S 6 94 31 2
EURL S-8.2 S 0 100 33 0
EURL S-8.3 R 100 0 33 0
EURL S-8.4 R 100 0 33 0
EURL S-8.5 S 6 94 31 2
EURL S-8.6 R 100 0 33 0
EURL S-8.7 S 3 97 32 1
EURL S-8.8 R 97 3 32 1
EURL S-8.1 S 0 100 34 0
EURL S-8.2 S 0 100 34 0
EURL S-8.3 R 100 0 34 0
EURL S-8.4 R 100 0 34 0
EURL S-8.5 R 100 0 34 0
EURL S-8.6 R 100 0 34 0
EURL S-8.7 S 0 100 34 0
EURL S-8.8 R 97 3 33 1
EURL S-8.1 S 0 100 34 0
EURL S-8.2 S 0 100 34 0
EURL S-8.3 S 0 100 34 0
EURL S-8.4 S 0 100 34 0
EURL S-8.5 S 0 100 34 0
EURL S-8.6 R 100 0 34 0
EURL S-8.7 S 0 100 34 0
EURL S-8.8 R 97 3 33 1
*Strain/antimicrobial-combination excluded from the evaluation
Trimethoprim, TMP
Meropenem, MER
Tetracycline, TET
Sulfamethoxazole, SMX
Nalidixic acid, NAL
Gentamicin, GEN
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Campylobacter  - expected and obtained interpretation
 
Antimicrobial Strain Expected % R % S No. 
correct
No. 
incorrect
EURL C-8.1 R 93% 7% 28 2
EURL C-8.2 S 0% 100% 30 0
EURL C-8.3 R 93% 7% 27 2
EURL C-8.4 S 4% 96% 26 1
EURL C-8.5 R 97% 3% 29 1
EURL C-8.6 S 3% 97% 29 1
EURL C-8.7 S 3% 97% 29 1
EURL C-8.8 R 100% 0% 30 0
EURL C-8.1 R 97% 3% 29 1
EURL C-8.2 R 97% 3% 29 1
EURL C-8.3 S 3% 97% 28 1
EURL C-8.4 S 0% 100% 27 0
EURL C-8.5 S 3% 97% 29 1
EURL C-8.6 S 3% 97% 29 1
EURL C-8.7 S 0% 100% 30 0
EURL C-8.8 S 3% 97% 29 1
EURL C-8.1 S 0% 100% 30 0
EURL C-8.2 S 0% 100% 30 0
EURL C-8.3 S 0% 100% 29 0
EURL C-8.4 S 0% 100% 27 0
EURL C-8.5 S 0% 100% 30 0
EURL C-8.6 S 0% 100% 30 0
EURL C-8.7 S 3% 97% 29 1
EURL C-8.8 S 0% 100% 30 0
EURL C-8.1 R 97% 3% 29 1
EURL C-8.2 S 3% 97% 29 1
EURL C-8.3 R 90% 10% 26 3
EURL C-8.4 R 92% 8% 24 2
EURL C-8.5 R 97% 3% 29 1
EURL C-8.6 S 17% 83% 25 5
EURL C-8.7 S 7% 93% 28 2
EURL C-8.8 R 97% 3% 29 1
EURL C-8.1 R 97% 3% 29 1
EURL C-8.2 S 7% 93% 28 2
EURL C-8.3 S 3% 97% 28 1
EURL C-8.4 S 4% 96% 26 1
EURL C-8.5 S 3% 97% 29 1
EURL C-8.6 R 100% 0% 30 0
EURL C-8.7 S 7% 93% 28 2
EURL C-8.8 R 100% 0% 30 0
EURL C-8.1 R 79% 21% 23 6
EURL C-8.2 S 0% 100% 30 0
EURL C-8.3 R 93% 7% 27 2
EURL C-8.4 R 96% 4% 26 1
EURL C-8.5 S 0% 100% 30 0
EURL C-8.6 R 100% 0% 30 0
EURL C-8.7 S 3% 97% 29 1
EURL C-8.8 R 100% 0% 30 0
Ciprofloxacin, CIP
Tetracycline, TET
Streptomycin, STR
Nalidixic acid, NAL
Gentamicin, GEN
Erythromycin, ERY
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Deviations - Salmonella
Lab no. Strain Antimicrobial Obtained 
interpretation
Obtained 
value
Expected 
interpretation
Expected MIC / 
ESBL conclusion
Method 
used
6 EURL S-8.7 ESBL test conclusion Unusual pt ESBL MIC
11 EURL S-8.1 Ciprofloxacin, CIP S 0.06 R = 0.25 MIC
12 EURL S-8.7 Ciprofloxacin, CIP R 0.12 S = 0.03 MIC
15 EURL S-8.1 Ciprofloxacin, CIP S 19 R = 0.25 DD
15 EURL S-8.5 Ciprofloxacin, CIP S R = 0.5 DD
15 EURL S-8.6 Ciprofloxacin, CIP S R = 1 DD
18 EURL S-8.7 ESBL test conclusion Unusual pt ESBL MIC
22 EURL S-8.3 ESBL test conclusion Unusual pt Not ESBL MIC
23 EURL S-8.2 Colistin, COL R 4 S <= 1 MIC
23 EURL S-8.3 Colistin, COL R 4 S <= 1 MIC
26 EURL S-8.5 Nalidixic acid, NAL S <=4 R > 64 MIC
30 EURL S-8.7 ESBL test conclusion Unusual pt ESBL MIC
33 EURL S-8.4 Nalidixic acid, NAL S >128 R > 64 MIC
39 EURL S-8.5 Ceftazidime, CAZ R 1 S = 1 MIC
40 EURL S-8.5 Sulfamethoxazole, SMX R 15 S <= 64 DD
41 EURL S-8.2 Colistin, COL R 4 S <= 1 MIC
41 EURL S-8.6 ESBL test conclusion Unusual pt ESBL MIC
42 EURL S-8.8 Ampicillin,Â AMP S 2 R > 32 MIC
42 EURL S-8.8 Chloramphenicol, CHL S 8 R > 64 MIC
42 EURL S-8.8 Sulfamethoxazole, SMX S 64 R > 1024 MIC
42 EURL S-8.8 Tetracycline, TET S 2 R > 32 MIC
42 EURL S-8.8 Trimethoprim, TMP S <=0.05 R > 32 MIC
45 EURL S-8.1 Sulfamethoxazole, SMX R 16.9 S <= 64 DD
45 EURL S-8.3 Chloramphenicol, CHL R 0 S = 8 DD
56 EURL S-8.1 Sulfamethoxazole, SMX R 512 S <= 64 DD
56 EURL S-8.7 ESBL test conclusion Unusual pt ESBL DD
58 EURL S-8.1 ESBL test conclusion pAmpC Not ESBL MIC
58 EURL S-8.2 ESBL test conclusion ESBL Not ESBL MIC
58 EURL S-8.3 ESBL test conclusion pAmpC Not ESBL MIC
58 EURL S-8.5 Ceftazidime, CAZ R >16 S = 1 MIC
58 EURL S-8.5 ESBL test conclusion Not ESBL Unusual pt MIC
58 EURL S-8.5 Gentamicin, GEN R 16 S <= 0.5 MIC
58 EURL S-8.5 Sulfamethoxazole, SMX R >1024 S <= 64 MIC
58 EURL S-8.7 ESBL test conclusion Not ESBL ESBL MIC
58 EURL S-8.7 Sulfamethoxazole, SMX R 1024 S <= 64 MIC
58 EURL S-8.8 Cefotaxime, CTX R >4 S <= 0.12 MIC
58 EURL S-8.8 Ceftazidime, CAZ R >16 S = 0.25 MIC
58 EURL S-8.8 Colistin, COL R 4 S <= 1 MIC
58 EURL S-8.8 ESBL test conclusion pAmpC Not ESBL MIC
AGA Agar dilution
DD Disk diffusion
ET E-test
MIC Microbroth dilution
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Deviations - Campylobacter
Lab no. Strain Antimicrobial Obtained interpretation
Obtained 
value
Expected 
interpretation
Expected 
MIC
Method 
used
4 EURL C-8.6 Nalidixic acid, NAL R 32 S = 16 MIC
4 EURL C-8.8 Erythromycin, ERY R 32 S <= 0.5 MIC
6 EURL C-8.1 Tetracycline, TET S <= 2 R = 8 MIC
6 EURL C-8.2 Streptomycin, STR R <= 4 S = 2 MIC
6 EURL C-8.3 Nalidixic acid, NAL S <= 4 R > 64 MIC
6 EURL C-8.3 Tetracycline, TET S <= 1 R > 16 MIC
6 EURL C-8.3 Ciprofloxacin, CIP S <= 0.06 R > 4 MIC
6 EURL C-8.3 Erythromycin, ERY R > 32 S = 2 MIC
6 EURL C-8.6 Ciprofloxacin, CIP R <= 0.12 S = 0.25 MIC
12 EURL C-8.1 Tetracycline, TET S 16 R = 8 MIC
12 EURL C-8.2 Streptomycin, STR R 8 S = 2 MIC
12 EURL C-8.6 Nalidixic acid, NAL R 32 S = 16 MIC
14 EURL C-8.1 Tetracycline, TET S 1 R = 8 MIC
14 EURL C-8.4 Nalidixic acid, NAL S 16 R = 64 MIC
17 EURL C-8.4 Nalidixic acid, NAL S 16 R = 64 MIC
20 EURL C-8.4 Streptomycin, STR R 16 S <= 1 MIC
21 EURL C-8.1 Tetracycline, TET S 2 R = 8 MIC
22 EURL C-8.3 Ciprofloxacin, CIP S =0.25 R > 4 MIC
22 EURL C-8.3 Nalidixic acid, NAL S <2 R > 64 MIC
22 EURL C-8.3 Streptomycin, STR R =8 S <= 1 MIC
22 EURL C-8.4 Campylobacter type C. jejuni
22 EURL C-8.7 Nalidixic acid, NAL R >64 S = 4 MIC
22 EURL C-8.7 Ciprofloxacin, CIP R =4 S <= 0.06 MIC
22 EURL C-8.7 Tetracycline, TET R =16 S = 0.5 MIC
22 EURL C-8.7 Streptomycin, STR R =16 S <= 1 MIC
22 EURL C-8.7 Gentamicin, GEN R =16 S = 0.25 MIC
23 EURL C-8.1 Campylobacter type C. coli
23 EURL C-8.2 Campylobacter type C. coli
23 EURL C-8.3 Campylobacter type C. jejuni
23 EURL C-8.4 Campylobacter type C. jejuni
23 EURL C-8.4 Ciprofloxacin, CIP R 1 S = 0.5 MIC
23 EURL C-8.5 Campylobacter type C. jejuni
23 EURL C-8.6 Campylobacter type C. coli
23 EURL C-8.7 Campylobacter type C. coli
23 EURL C-8.8 Campylobacter type C. coli
29 EURL C-8.3 Nalidixic acid, NAL S <1 R > 64 MIC
29 EURL C-8.3 Tetracycline, TET S 2 R > 16 MIC
29 EURL C-8.5 Nalidixic acid, NAL S 16 R > 64 MIC
29 EURL C-8.5 Ciprofloxacin, CIP S 1 R > 4 MIC
29 EURL C-8.5 Streptomycin, STR R 4 S = 2 MIC
29 EURL C-8.8 Nalidixic acid, NAL S 32 R = 64 MIC
36 EURL C-8.5 Campylobacter type C. coli C. jejuni
36 EURL C-8.6 Campylobacter type C. jejuni C. coli
36 EURL C-8.6 Nalidixic acid, NAL R 32 S = 16 MIC
37 EURL C-8.1 Nalidixic acid, NAL S <=2 R > 64 AGA
37 EURL C-8.1 Tetracycline, TET S <=0.125 R = 8 AGA
37 EURL C-8.1 Ciprofloxacin, CIP S <=0.06 R > 4 AGA
37 EURL C-8.1 Streptomycin, STR S 4 R > 16 AGA
37 EURL C-8.1 Erythromycin, ERY S 4 R > 32 AGA
37 EURL C-8.2 Erythromycin, ERY S 4 R > 32 AGA
40 EURL C-8.1 Tetracycline, TET S 2 R = 8 MIC
40 EURL C-8.6 Campylobacter type C. jejuni C. coli
40 EURL C-8.7 Nalidixic acid, NAL R 32 S = 4 MIC
42 EURL C-8.6 Erythromycin, ERY R 4 S = 4 MIC
44 EURL C-8.1 Ciprofloxacin, CIP S <1 R > 4 AGA
44 EURL C-8.4 Tetracycline, TET S <2 R > 16 AGA
44 EURL C-8.6 Nalidixic acid, NAL R >16<32 S = 16 AGA
44 EURL C-8.7 Streptomycin, STR R >4 S <= 1 AGA
45 EURL C-8.6 Nalidixic acid, NAL R 32 S = 16 MIC
58 EURL C-8.2 Nalidixic acid, NAL R 32 S = 8 MIC
58 EURL C-8.5 Erythromycin, ERY R 32 S = 2 MIC
AGA Agar dilution
MIC Microbroth dilution
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Genotypic characterization (optional)
Lab no. Strain Gene tested
Not 
detected Primer used 5’→3’ Primer used 3’→5’ PCR-method Reference
I EURL S-8.4 VIM -2 Whole genome sequencing
I EURL S-8.5 CTX M-9 Whole genome sequencing
I EURL S-8.6 CTX M-3 Whole genome sequencing
I EURL S-8.7 TEM -52 Whole genome sequencing
III EURL S-8.4 TEM -1 PCR (published) Olesen et al., MDR 2004
III EURL S-8.4 VIM -2 PCR (published) Dallene et al. JAC 2010
III EURL S-8.4 ACC X PCR (published) Perez-Perez JCM 2002
III EURL S-8.4 ACT X PCR (published) Perez-Perez JCM 2002
III EURL S-8.4 CMY-2 X PCR (published) Zhao et al. AAC 2001
III EURL S-8.4 CTX X PCR (published) Bachelor et al. AAC 2005
III EURL S-8.4 DHA X PCR (published) Perez-Perez JCM 2002
III EURL S-8.4 FOX X PCR (published) Perez-Perez JCM 2002
III EURL S-8.4 GES X Provided by EURL-AR, H. Hasman
III EURL S-8.4 IMP X PCR (published) Dallene et al. JAC 2010
III EURL S-8.4 KPC X PCR (published) Dallene et al. JAC 2010
III EURL S-8.4 MOX X PCR (published) Perez-Perez JCM 2002
III EURL S-8.4 NDM X PCR (published) Poirel et al. DMID 2011
III EURL S-8.4 OXA X See comment (several families were tested)
III EURL S-8.4 PER X Provided by EURL-AR, H. Hasman
III EURL S-8.4 SHV X PCR (published) Weill et al, JCM 2004
III EURL S-8.4 VEB X PCR (published) Provided by EURL-AR, H. Hasman
III EURL S-8.5 CTX M-9 PCR (published) Paauw et al., EID 2006; see comments
III EURL S-8.5 TEM -1 PCR (published) Olesen et al., MDR 2004
III EURL S-8.5 ACC X See 8.4
III EURL S-8.5 ACT X See 8.4
III EURL S-8.5 CMY X See 8.4
III EURL S-8.5 DHA X See 8.4
III EURL S-8.5 FOX X See 8.4
III EURL S-8.5 GES X See 8.4
III EURL S-8.5 IMP X See 8.4
III EURL S-8.5 KPC X See 8.4
III EURL S-8.5 MOX X See 8.4
III EURL S-8.5 NDM X See 8.4
III EURL S-8.5 OXA X several families were tested see 8.4
III EURL S-8.5 PER X See 8.4
III EURL S-8.5 SHV X See 8.4
III EURL S-8.5 VEB X See 8.4
III EURL S-8.5 VIM X See 8.4
III EURL S-8.6 CTX M-3 PCR (published) Carattoli et al., JCM 2008
III EURL S-8.6 OXA -30 PCR (published) Guerra et al., AAC 2000
III EURL S-8.6 ACC X
III EURL S-8.6 ACT X
III EURL S-8.6 CMY X
III EURL S-8.6 DHA X
III EURL S-8.6 FOX X
III EURL S-8.6 GES X
III EURL S-8.6 IMP X
III EURL S-8.6 KPC X
III EURL S-8.6 MOX X
III EURL S-8.6 NDM X
III EURL S-8.6 PER X
III EURL S-8.6 SHV X
III EURL S-8.6 TEM X
III EURL S-8.6 VEB X
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Lab no. Strain Gene tested
Not 
detected Primer used 5’→3’ Primer used 3’→5’ PCR-method Reference
III EURL S-8.6 VIM X
III EURL S-8.7 TEM -52 PCR (published) Olesen et al., MDR 2004
III EURL S-8.7 ACC X
III EURL S-8.7 ACT X
III EURL S-8.7 CMY X
III EURL S-8.7 CTX X
III EURL S-8.7 DHA X
III EURL S-8.7 FOX X
III EURL S-8.7 GES X
III EURL S-8.7 IMP X
III EURL S-8.7 KPC X
III EURL S-8.7 MOX X
III EURL S-8.7 NDM X
III EURL S-8.7 OXA X
III EURL S-8.7 PER X
III EURL S-8.7 SHV X
III EURL S-8.7 VEB X
III EURL S-8.7 VIM X
IV EURL S-8.4 TEM -1 PCR (published) Dierikx, Vet Mic (2010);145:273-8
IV EURL S-8.4 VIM PCR (published) Ellington, JAC (2007); 59:321-322
IV EURL S-8.5 CTX M-9 PCR (published) Paauw A, EID 2006;12:807-12
IV EURL S-8.6 CTX M-3 PCR (published) Carattoli A, JCM (2008);46:103-8
IV EURL S-8.7 TEM -52 PCR (published) Dierikx, Vet Mic (2010);145:273-8
VI EURL S-8.1 ACC-1 X AGCCTCAGCAGCCGGTTAC CCGGATCAACTAACGGCTTC PCR (published) J Clin Microbiol. 2002 Jun;40(6):2153-62
VI EURL S-8.1 CMY X ATGCAACAACGACAATCC CATCGTCATGCTGGCCAA PCR (published) . Antimicrob Agents Chemother 2006 50:618-24.
VI EURL S-8.1 CMY X GCACTTAGCCACCTATACGGCAG CCTGGCGCATTCTTGAAAAGC PCR (published) J. Antimicrob. Chemother. 2006 56:115-121
VI EURL S-8.1 CTX X ATGTGCAGYACCAGTAARGTKATGGC CCGCTSRTTCTGGTSACYTAYTTYACCCA PCR (published) Pediatr Infect Dis J. 28:814-818.2009
VI EURL S-8.1 DHA-1 X CTGATGAAAAAATCGTTATC TATTTTGAGTGCACTGGAAT PCR (published) Journal of Antimicrobial Chemotherapy (2009) 64, 1
VI EURL S-8.1 OXA-10 X CGCCAGAGAAGTTGGCGAAGTAAG CCGCAGTTAATCAAGTGGAGTTTC PCR (published) Int J Antimicrob Agents. 2011 Apr; 37 (4):356-9.
VI EURL S-8.1 OXA-30 X ATGAAAAACACAATACATATCAACTTCG AATGCGATCACCCATTCTAAAGACAC PCR (published) Journal of Antimicrobial Chemotherapy (2009) 64, 1
VI EURL S-8.1 SHV X TTATCTCCCTGTTAGCCACC CCGAGCGAAATCAGCAAATC PCR (published) FEMS Microbiol Lett. 1997. 152:163-7.
VI EURL S-8.1 TEM X GCGGAACCCCTATTTG CTCACTGATTAAGCATTGGT PCR (published) Antimicrobial Agents and Chemotherapy. 2009. 53:17
VI EURL S-8.2 ACC-1 X AGCCTCAGCAGCCGGTTAC CCGGATCAACTAACGGCTTC PCR (published) J Clin Microbiol. 2002 Jun;40(6):2153-62
VI EURL S-8.2 CMY X ATGCAACAACGACAATCC CATCGTCATGCTGGCCAA PCR (published) Antimicrob Agents Chemother 2006 50:618-24.
VI EURL S-8.2 CMY X GCACTTAGCCACCTATACGGCAG CCTGGCGCATTCTTGAAAAGC PCR (published) J. Antimicrob. Chemother. 2006 56:115-121
VI EURL S-8.2 CTX X ATGTGCAGYACCAGTAARGTKATGGC CCGCTSRTTCTGGTSACYTAYTTYACCCA PCR (published) Pediatr Infect Dis J. 28:814-818.2009
VI EURL S-8.2 DHA-1 X CTGATGAAAAAATCGTTATC TATTTTGAGTGCACTGGAAT PCR (published) Journal of Antimicrobial Chemotherapy (2009) 64, 1
VI EURL S-8.2 OXA-10 X CGCCAGAGAAGTTGGCGAAGTAAG CCGCAGTTAATCAAGTGGAGTTTC PCR (published) Int J Antimicrob Agents. 2011 Apr; 37 (4):356-9.
VI EURL S-8.2 OXA-30 X ATGAAAAACACAATACATATCAACTTCG AATGCGATCACCCATTCTAAAGACAC PCR (published) Journal of Antimicrobial Chemotherapy (2009) 64
VI EURL S-8.2 SHV X TTATCTCCCTGTTAGCCACC CCGAGCGAAATCAGCAAATC PCR (published) FEMS Microbiol Lett. 1997. 152:163-7.
VI EURL S-8.2 TEM X GCGGAACCCCTATTTG CTCACTGATTAAGCATTGGT PCR (published) Antimicrobial Agents and Chemotherapy. 2009. 53:17
VI EURL S-8.3 ACC-1 X AGCCTCAGCAGCCGGTTAC CCGGATCAACTAACGGCTTC PCR (published) J Clin Microbiol. 2002 Jun;40(6):2153-62
VI EURL S-8.3 CMY X ATGCAACAACGACAATCC CATCGTCATGCTGGCCAA PCR (published) Antimicrob Agents Chemother 2006 50:618-24.
VI EURL S-8.3 CMY X GCACTTAGCCACCTATACGGCAG CCTGGCGCATTCTTGAAAAGC PCR (published) J. Antimicrob. Chemother. 2006 56:115-121
VI EURL S-8.3 CTX X ATGTGCAGYACCAGTAARGTKATGGC CCGCTSRTTCTGGTSACYTAYTTYACCCA PCR (published) Pediatr Infect Dis J. 28:814-818.2009
VI EURL S-8.3 DHA-1 X CTGATGAAAAAATCGTTATC TATTTTGAGTGCACTGGAAT PCR (published) Journal of Antimicrobial Chemotherapy (2009) 64, 1
VI EURL S-8.3 OXA-10 X CGCCAGAGAAGTTGGCGAAGTAAG CCGCAGTTAATCAAGTGGAGTTTC PCR (published) Int J Antimicrob Agents. 2011 Apr; 37 (4):356-9.
VI EURL S-8.3 OXA-30 X ATGAAAAACACAATACATATCAACTTCG AATGCGATCACCCATTCTAAAGACAC PCR (published) Journal of Antimicrobial Chemotherapy (2009) 64, 1
VI EURL S-8.3 SHV X TTATCTCCCTGTTAGCCACC CCGAGCGAAATCAGCAAATC PCR (published) FEMS Microbiol Lett. 1997. 152:163-7.
VI EURL S-8.3 TEM X GCGGAACCCCTATTTG CTCACTGATTAAGCATTGGT PCR (published) Antimicrobial Agents and Chemotherapy. 2009. 53:17
VI EURL S-8.4 TEM -1 GCGGAACCCCTATTTG CTCACTGATTAAGCATTGGT PCR (published) Antimicrobial Agents and Chemotherapy. 2009. 53:17
VI EURL S-8.4 ACC-1 X AGCCTCAGCAGCCGGTTAC CCGGATCAACTAACGGCTTC PCR (published) J Clin Microbiol. 2002 Jun;40(6):2153-62
VI EURL S-8.4 CMY X ATGCAACAACGACAATCC CATCGTCATGCTGGCCAA PCR (published) Antimicrob Agents Chemother 2006 50:618-24
VI EURL S-8.4 CMY X GCACTTAGCCACCTATACGGCAG CCTGGCGCATTCTTGAAAAGC PCR (published) J. Antimicrob. Chemother. 2006 56:115-121
VI EURL S-8.4 CTX X ATGTGCAGYACCAGTAARGTKATGGC CCGCTSRTTCTGGTSACYTAYTTYACCCA PCR (published) Pediatr Infect Dis J. 28:814-818.2009
VI EURL S-8.4 DHA-1 X CTGATGAAAAAATCGTTATC TATTTTGAGTGCACTGGAAT PCR (published) Journal of Antimicrobial Chemotherapy (2009) 64, 1
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VI EURL S-8.4 OXA-10 X CGCCAGAGAAGTTGGCGAAGTAAG CCGCAGTTAATCAAGTGGAGTTTC PCR (published) Int J Antimicrob Agents. 2011 Apr; 37 (4):356-9.
VI EURL S-8.4 OXA-30 X ATGAAAAACACAATACATATCAACTTCG AATGCGATCACCCATTCTAAAGACAC PCR (published) Journal of Antimicrobial Chemotherapy (2009) 64, 1
VI EURL S-8.4 SHV X TTATCTCCCTGTTAGCCACC CCGAGCGAAATCAGCAAATC PCR (published) FEMS Microbiol Lett. 1997. 152:163-7.
VI EURL S-8.5 CTX M-9 ATGTGCAGYACCAGTAARGTKATGGC CCGCTSRTTCTGGTSACYTAYTTYACCCA PCR (published) Pediatr Infect Dis J. 2009 28:814-818.
VI EURL S-8.5 TEM -1 GCGGAACCCCTATTTG CTCACTGATTAAGCATTGGT PCR (published) Antimicrobial Agents and Chemotherapy. 2009. 53:17
VI EURL S-8.5 ACC-1 X AGCCTCAGCAGCCGGTTAC CCGGATCAACTAACGGCTTC PCR (published) J Clin Microbiol. 2002 Jun;40(6):2153-62
VI EURL S-8.5 CMY X ATGCAACAACGACAATCC CATCGTCATGCTGGCCAA PCR (published) Antimicrob Agents Chemother 2006 50:618-24.
VI EURL S-8.5 CMY X GCACTTAGCCACCTATACGGCAG CCTGGCGCATTCTTGAAAAGC PCR (published) J. Antimicrob. Chemother. 2006 56:115-121
VI EURL S-8.5 DHA-1 X CTGATGAAAAAATCGTTATC TATTTTGAGTGCACTGGAAT PCR (published) Journal of Antimicrobial Chemotherapy (2009) 64, 1
VI EURL S-8.5 OXA-10 X CGCCAGAGAAGTTGGCGAAGTAAG CCGCAGTTAATCAAGTGGAGTTTC PCR (published) Int J Antimicrob Agents. 2011 Apr; 37 (4):356-9.
VI EURL S-8.5 OXA-30 X ATGAAAAACACAATACATATCAACTTCG AATGCGATCACCCATTCTAAAGACAC PCR (published) Journal of Antimicrobial Chemotherapy (2009) 64, 1
VI EURL S-8.5 SHV X TTATCTCCCTGTTAGCCACC CCGAGCGAAATCAGCAAATC PCR (published) FEMS Microbiol Lett. 1997. 152:163-7.
VI EURL S-8.6 CTX M-3 ATGTGCAGYACCAGTAARGTKATGGC CCGCTSRTTCTGGTSACYTAYTTYACCCA PCR (published) Pediatr Infect Dis J. 28:814-818.2009
VI EURL S-8.6 OXA -30 ATGAAAAACACAATACATATCAACTTCG AATGCGATCACCCATTCTAAAGACAC PCR (published) Journal of Antimicrobial Chemotherapy (2009) 64, 1
VI EURL S-8.6 ACC-1 X AGCCTCAGCAGCCGGTTAC CCGGATCAACTAACGGCTTC PCR (published) J Clin Microbiol. 2002 Jun;40(6):2153-62
VI EURL S-8.6 CMY X ATGCAACAACGACAATCC CATCGTCATGCTGGCCAA PCR (published) Antimicrob Agents Chemother 2006 50:618-24.
VI EURL S-8.6 CMY X GCACTTAGCCACCTATACGGCAG CCTGGCGCATTCTTGAAAAGC PCR (published) J. Antimicrob. Chemother.2006 56:115-121
VI EURL S-8.6 DHA-1 X CTGATGAAAAAATCGTTATC TATTTTGAGTGCACTGGAAT PCR (published) Journal of Antimicrobial Chemotherapy (2009) 64, 1
VI EURL S-8.6 OXA-10 X CGCCAGAGAAGTTGGCGAAGTAAG CCGCAGTTAATCAAGTGGAGTTTC PCR (published) Int J Antimicrob Agents. 2011 Apr; 37 (4):356-9.
VI EURL S-8.6 SHV X TTATCTCCCTGTTAGCCACC CCGAGCGAAATCAGCAAATC PCR (published) FEMS Microbiol Lett. 1997. 152:163-7.
VI EURL S-8.6 TEM X GCGGAACCCCTATTTG CTCACTGATTAAGCATTGGT PCR (published) Antimicrobial Agents and Chemotherapy. 2009. 53:17
VI EURL S-8.7 TEM -52 GCGGAACCCCTATTTG CTCACTGATTAAGCATTGGT PCR (published) Antimicrobial Agents and Chemotherapy. 2009. 53:17
VI EURL S-8.7 ACC-1 X AGCCTCAGCAGCCGGTTAC CCGGATCAACTAACGGCTTC PCR (published) J Clin Microbiol. 2002 Jun;40(6):2153-62
VI EURL S-8.7 CMY X ATGCAACAACGACAATCC CATCGTCATGCTGGCCAA PCR (published) Antimicrob Agents Chemother 2006 50:618-24
VI EURL S-8.7 CMY X GCACTTAGCCACCTATACGGCAG CCTGGCGCATTCTTGAAAAGC PCR (published) J. Antimicrob. Chemother. 2006 56:115-121
VI EURL S-8.7 CTX X ATGTGCAGYACCAGTAARGTKATGGC CCGCTSRTTCTGGTSACYTAYTTYACCCA PCR (published) Pediatr Infect Dis J. 28:814-818.2009
VI EURL S-8.7 DHA-1 X CTGATGAAAAAATCGTTATC TATTTTGAGTGCACTGGAAT PCR (published) Journal of Antimicrobial Chemotherapy (2009) 64, 1
VI EURL S-8.7 OXA-10 X CGCCAGAGAAGTTGGCGAAGTAAG CCGCAGTTAATCAAGTGGAGTTTC PCR (published) Int J Antimicrob Agents. 2011 Apr; 37 (4):356-9.
VI EURL S-8.7 OXA-30 X ATGAAAAACACAATACATATCAACTTCG AATGCGATCACCCATTCTAAAGACAC PCR (published) Journal of Antimicrobial Chemotherapy (2009) 64,
VI EURL S-8.7 SHV X TTATCTCCCTGTTAGCCACC CCGAGCGAAATCAGCAAATC PCR (published) FEMS Microbiol Lett. 1997. 152:163-7.
VI EURL S-8.8 ACC-1 X AGCCTCAGCAGCCGGTTAC CCGGATCAACTAACGGCTTC PCR (published) J Clin Microbiol. 2002 Jun;40(6):2153-62
VI EURL S-8.8 CMY X ATGCAACAACGACAATCC CATCGTCATGCTGGCCAA PCR (published) Antimicrob Agents Chemother 2006 50:618-24.
VI EURL S-8.8 CMY X GCACTTAGCCACCTATACGGCAG CCTGGCGCATTCTTGAAAAGC PCR (published) J. Antimicrob. Chemother.2006 56:115-121
VI EURL S-8.8 CTX X ATGTGCAGYACCAGTAARGTKATGGC CCGCTSRTTCTGGTSACYTAYTTYACCCA PCR (published) Pediatr Infect Dis J. 28:814-818.2009
VI EURL S-8.8 DHA-1 X CTGATGAAAAAATCGTTATC ATTCCAGTGCACTCAAAATA PCR (published) Journal of Antimicrobial Chemotherapy (2009) 64, 1
VI EURL S-8.8 OXA-10 X CGCCAGAGAAGTTGGCGAAGTAAG CCGCAGTTAATCAAGTGGAGTTTC PCR (published) Int J Antimicrob Agents. 2011 Apr; 37 (4):356-9.
VI EURL S-8.8 OXA-30 X ATGAAAAACACAATACATATCAACTTCG AATGCGATCACCCATTCTAAAGACAC PCR (published) Journal of Antimicrobial Chemotherapy (2009) 64, 1
VI EURL S-8.8 SHV X TTATCTCCCTGTTAGCCACC CCGAGCGAAATCAGCAAATC PCR (published) FEMS Microbiol Lett. 1997. 152:163-7.
VI EURL S-8.8 TEM X GCGGAACCCCTATTTG CTCACTGATTAAGCATTGGT PCR (published) Antimicrobial Agents and Chemotherapy. 2009. 53:17
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VII EURL S-8.4 SHV
VII EURL S-8.4 TEM PCR (published) Fang, H., F. Ataker, et al. (2008)
VII EURL S-8.4 ACC X
VII EURL S-8.4 ACT X
VII EURL S-8.4 CMY X
VII EURL S-8.4 CTXM-1 X PCR (published) Woodford, N., E. J. Fagan, et al. (2006)
VII EURL S-8.4 CTXM-2 X
VII EURL S-8.4 CTXM-26 X
VII EURL S-8.4 CTXM-8 X
VII EURL S-8.4 CTXM-9 X
VII EURL S-8.4 DHA X
VII EURL S-8.4 FOX X
VII EURL S-8.4 MOX X PCR (published) Perez-Perez, F. J. and N. D. Hanson (2002)
VII EURL S-8.4 OXA X
VII EURL S-8.5 CTX M-9
VII EURL S-8.5 TEM
VII EURL S-8.5 ACC X
VII EURL S-8.5 ACT X
VII EURL S-8.5 CMY X
VII EURL S-8.5 CTXM-1 X PCR (published) Woodford, N., E. J. Fagan, et al. (2006)
VII EURL S-8.5 CTXM-2 X
VII EURL S-8.5 CTXM-26 X
VII EURL S-8.5 CTXM-8 X
VII EURL S-8.5 DHA X
VII EURL S-8.5 FOX X
VII EURL S-8.5 MOX X PCR (published) Perez-Perez, F. J. and N. D. Hanson (2002)
VII EURL S-8.5 OXA X PCR (published) Fang, H., F. Ataker, et al. (2008)
VII EURL S-8.5 SHV X
VII EURL S-8.6 CTX M-1 PCR (published) Woodford, N., E. J. Fagan, et al. (2006).
VII EURL S-8.6 OXA
VII EURL S-8.6 ACC X
VII EURL S-8.6 ACT X
VII EURL S-8.6 CMY X
VII EURL S-8.6 CTXM-2 X
VII EURL S-8.6 CTXM-26 X
VII EURL S-8.6 CTXM-8 X
VII EURL S-8.6 CTXM-9 X
VII EURL S-8.6 DHA X
VII EURL S-8.6 FOX X
VII EURL S-8.6 MOX X PCR (published) Perez-Perez, F. J. and N. D. Hanson (2002)
VII EURL S-8.6 SHV X PCR (published) Fang, H., F. Ataker, et al. (2008)
VII EURL S-8.6 TEM X
VII EURL S-8.7 TEM
VII EURL S-8.7 ACC X
VII EURL S-8.7 ACT X
VII EURL S-8.7 CMY X
VII EURL S-8.7 CTXM-1 X PCR (published) Woodford, N., E. J. Fagan, et al. (2006)
VII EURL S-8.7 CTXM-2 X
VII EURL S-8.7 CTXM-26 X
VII EURL S-8.7 CTXM-8 X
VII EURL S-8.7 CTXM-9 X
VII EURL S-8.7 DHA X
VII EURL S-8.7 FOX X
VII EURL S-8.7 MOX X PCR (published) Perez-Perez, F. J. and N. D. Hanson (2002)
VII EURL S-8.7 OXA X
VII EURL S-8.7 SHV X PCR (published) Fang, H., F. Ataker, et al. (2008)
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X EURL S-8.4 TEM -1 PCR (published) JAC 2010; 65: 490–495;doi:10.1093/jac/dkp498
X EURL S-8.4 VIM -2 PCR (published) JAC 2010; 65: 490–495;doi:10.1093/jac/dkp498
X EURL S-8.5 CTX M-9 PCR (published) JAC 2010; 65: 490–495;doi:10.1093/jac/dkp498
X EURL S-8.5 TEM -1 PCR (published) JAC 2010; 65: 490–495;doi:10.1093/jac/dkp498
X EURL S-8.6 CTX M-3 PCR (published) JAC 2010; 65: 490–495;doi:10.1093/jac/dkp498
X EURL S-8.6 OXA -30 PCR (published) JAC 2010; 65: 490–495;doi:10.1093/jac/dkp498
X EURL S-8.7 TEM -52 PCR (published) JAC 2010; 65: 490–495;doi:10.1093/jac/dkp498
XI EURL S-8.4 CTX PCR (published)
XI EURL S-8.4 TEM -1 PCR (published)
XI EURL S-8.5 CTX PCR (published)
XI EURL S-8.5 TEM PCR (published)
XI EURL S-8.6 CTX PCR (published)
XI EURL S-8.6 OXA PCR (published)
XI EURL S-8.7 CTX PCR (published)
XI EURL S-8.7 TEM PCR (published)
XIV EURL S-8.5 CTX M-9 PCR (published) Dallenne et al. 2010
XIV EURL S-8.5 TEM -1 PCR (published) Dallenne et al. 2010
XIV EURL S-8.6 CTX M-15 PCR (published) Dallenne et al. 2010
XIV EURL S-8.6 OXA -30 PCR (published) Dallenne et al. 2010
XIV EURL S-8.7 TEM -52 PCR (published) Dallenne et al. 2010
Legend: 
Fields shaded grey indicate that the gene was expected
Genes in bold were detected but not expected 
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